Cytomegalovirus infection is associated with an increase in aortic stiffness in older men which may be mediated in part by CD4 memory T-cells

Kirkham, Frances, Pera, Alejandra, Simanek, Amanda M, Bano, Aalia, Morrow, George, Reus, Bernhard, Caserta, Stefano, Smith, Helen E, Davies, Kevin A, Rajkumar, Chakravarthi and Kern, Florian (2021) Cytomegalovirus infection is associated with an increase in aortic stiffness in older men which may be mediated in part by CD4 memory T-cells. Theranostics. ISSN 1838-7640

This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/97889/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
Cytomegalovirus infection is associated with an increase in aortic stiffness in older men which may be mediated in part by CD4 memory T-cells

Short title: A CMV-associated increase in aortic stiffness in older men

Frances Kirkham¹#, Alejandra Pera²,³#, Amanda M. Simanek⁴, Aalia Bano¹, George Morrow¹§, Bernhard Reus⁵, Stefano Caserta⁶†, Helen E. Smith⁷, Kevin A Davies¹, Chakravarthi Rajkumar¹ and Florian Kern¹

1. Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.
2. Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
3. Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain
4. Joseph J. Zilber School of Public Health, University of Wisconsin-Milwaukee, USA
5. Department of Informatics, School of Engineering and Informatics, University of Sussex, Brighton, UK.
6. Department of Global Health and Infectious Diseases, Brighton and Sussex Medical School, Brighton, United Kingdom.
7. Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang Technological University Singapore.

#Both authors should be considered first authors
§Flow Cytometry Translational Technology Platform, UCL Cancer Institute, London, United Kingdom.
†School of Life Sciences University of Hull, Hull, UK.

*Corresponding author: Florian Kern, MD, Brighton and Sussex Medical School, Medical Research Building, Biology Road, University of Sussex Campus, Falmer, Brighton, BN1 9PS, E: T: +44 (0)1273 877671, E-mail: fkern@bsms.ac.uk.
Abstract

Human Cytomegalovirus (CMV) infection is associated with atherosclerosis, higher cardiovascular disease (CVD) risk, and an increase in memory T-cells (T\textsubscript{mem}). T-cells have also been implicated in CVD, independently of CMV infection. To better understand the CMV-associated CVD risk, we examined the association between CMV (IgG) serostatus and central aortic (carotid-to-femoral) pulse wave velocity (cfPWV), an early, independent predictor of CVD. We also investigated if such an association might be reflected by the distribution of T\textsubscript{mem} and/or other T-cell subsets.

Methods: Healthy older volunteers (60-93 years) underwent routine clinical and laboratory evaluation, including assessment of cfPWV in eligible participants. Flow-cytometry was used to assess proportions of memory T-cells, CD28\textsuperscript{null} T-cells, and CMV-specific T-cells. The following associations were examined: CMV serostatus/cfPWV, CMV serostatus/proportion of T\textsubscript{mem}, proportion of T\textsubscript{mem}/cfPWV, CD28\textsuperscript{null} T-cells/PWV, and CMV-specific T-cells/cfPWV. Linear regression models were used to adjust for age, sex, socioeconomic status, smoking, waist-to-hip ratio, cholesterol, and blood pressure as required.

Results: Statistically significant positive associations were found (P-values for the fully adjusted models are given): CMV serostatus/cfPWV in men (P \leq 0.01) but not in women, CMV serostatus/proportions of CD4 T\textsubscript{mem} in men (P \leq 0.05) but not in women; proportions of CD4 T\textsubscript{mem}/cfPWV among CMV seropositive (CMV+) people (P<=0.05) but not CMV seronegative (CMV-) people.

Conclusion: CMV infection increases the CVD risk of older men by increasing cfPWV. This may be mediated in part by increased proportions of CD4 T\textsubscript{mem}, higher numbers of which are found in CMV+ older people and more so among men than women. Given the high prevalence of CMV worldwide, our findings point to a significant global health issue. Novel strategies to mitigate the increased CVD risk associated with CMV may be required.

Key words: central aortic stiffness, pulse wave velocity, cardiovascular risk, human Cytomegalovirus (CMV), Memory T-cells
A CMV-associated increase in central aortic stiffness in older men but not women might be explained by a bigger CMV-induced increase in pro-inflammatory/proatherosclerotic CD4 memory T-cells in men.
Introduction

A recent meta-analysis of 10 studies across a total of 34,564 participants concluded that human Cytomegalovirus (CMV) infection (i.e., the status of being anti-CMV IgG seropositive, or ‘CMV+’) increases the overall risk of cardiovascular disease (CVD) by 22% [1]. However, the mechanisms underlying this association are not well understood. As CMV prevalence increases with age, the effects of CMV infection and aging are difficult to dissociate. CMV is often considered a confounder with respect to age-associated pathologies and vice versa. CMV infection has been directly associated with precursors to cardiovascular disease such as hypertension and atherosclerotic changes in a number of human and animal studies [2-4]. For example, a mouse model of murine CMV (MCMV) infection demonstrated that, apart from causing an increase in blood pressure, MCMV was independently a co-factor for aortic intimal thickening [3]. In humans, being CMV+ has also been found to be associated with increased blood pressure [4].

The exact mechanisms by which CMV infection contributes to CVD remain unclear, but there is increasing evidence that some of the major effects of CMV on the cardiovascular system are mediated by its impact on certain immune cell subsets, particularly antigen-experienced, memory-T-cells (T\textsubscript{mem}) [5-7]. T-cells in general, and particularly CD4 T-cells, have been shown to be associated with atherosclerosis and atherothrombosis [8]. Infection with CMV induces high frequencies of pro-inflammatory, CMV protein-specific effector T-cells [9, 10], but also increases the proportions of antigen-experienced CD4 and CD8 T-cells in general [9-11]. Since vascular endothelial cells are a primary target tissue for CMV infection [12], CMV-specific T-cells may be targeted to vascular endothelium causing local damage; however, upregulated adhesion molecules on damaged endothelium may also attract non-CMV-specific T-cells [13, 14]. A study in rats showed that intraperitoneal CMV infection, administered immediately after experimental vascular injury, significantly increased the neointimal response to that injury (i.e., intima to media ratio). Interestingly, this effect was independent of the presence of virus in the injured epithelium itself, suggesting that CMV-driven pro-inflammatory T-cells may non-specifically infiltrate injured vasculature [15].

Men and women differ with regards to age and CMV-associated changes to the immune system [6, 16], which may help explain sex differences in mortality from coronary heart disease and stroke [17]. For example, in older men CMV infection induces larger proportions of highly differentiated CD4 and CD8 effector memory T-cells than in older women [6]. Such effector cells may have a destabilizing effect on atherosclerotic plaques [8]. Older women, by contrast, have more regulatory T-cells than older men, which have a stabilizing effect on atheromatous lesions [8]. This might explain why atherosclerotic plaques are more stable in older women [18].

Compliance of the large elastic arteries is a well-established, early, and sensitive marker of cardiovascular risk, which can be measured non-invasively as central aortic pulse-wave velocity [19]. It is calculated from the path length travelled by the pulse wave in the carotid-to-femoral region and its transit time, and referred to as carotid-to-femoral pulse-wave velocity (cfPWV). cfPWV has a well-documented positive correlation with cardiovascular outcomes such as heart attacks and stroke, independently of traditional risk factors [20, 21].

It was recently shown that CMV infection is associated with increased cfPWV in chronic kidney disease (CKD) [22], the latter affecting 11-13% of people worldwide [23]. Since the prevalence of CMV infection (i.e. positive IgG serology) is about 80% in over 65 year-olds in European studies [24, 25] and even higher elsewhere [26, 27], any detrimental effect of CMV on cardiovascular health should be of major concern. Being able to
demonstrate a similar effect of CMV infection on cfPWV in generally healthy older people would significantly corroborate the role of CMV as a driver of CVD and underscore its relevance to global health [20, 21]. In the present work we examine if an association between CMV serostatus and cfPWV indeed exists in generally healthy older people. Also, in light of the suspected role of T-cells in the pathogenesis of atherosclerosis and cardiovascular disease [7, 8] and CMV’s role in driving memory T-cell expansion [5, 6], we examine the distribution of different antigen-experienced T-cell subsets (T_{mem}) as well as the size of the CMV-specific T-cell response across our population of older CMV+ and CMV- men and women. This allows us to examine the effect of T-cells on cfPWV that may be mediated by CMV serostatus and/or sex.
**Results**

_In older men but not women, CMV-infection is associated with increased cfPWV_

A possible association of CMV infection with an increase in cfPWV (as an indicator of CVD risk) was the primary focus of our study. Across our total cohort of older people (60-93 years) cfPWV (median) was within the reported normal range [28] with 8.9 m/s (IQR: 2.4 m/s) among 60-70 year-olds (N = 91), 9.8 m/s (IQR: 3.4 m/s) in 70-80 year-olds (N = 29), and 12.2 m/s (IQR: 3.3 m/s) in 80-90 year-olds (N = 15). The prevalence of CMV infection was 54% among those assessed in the vascular lab (a study flow-chart is provided in Figure S1).

In CMV+ men the median cfPWV was 1.1 m/s higher than in CMV- men (P = 0.022). Among women, the difference was in the opposite direction but not statistically significant (Table 1 and Figure S2). According to published normal ranges, a difference of 1 m/s roughly corresponds to an age difference of about 5-10 years in the investigated age group [28]. In order to confirm this important finding, we built linear regression models examining the association between CMV infection (positive IgG-serology) and cfPWV (Table 2) while adjusting for relevant covariates. In the entire cohort of N = 136 individuals (men and women) we observed no statistically significant association between CMV serostatus and cfPWV, neither in the crude nor adjusted models. However, since we had observed a significant difference in cfPWV between CMV+ and CMV- older men but not women, we added the interaction term ‘CMV serostatus*sex’ to the model. This term was significant at all levels of adjustment with P = 0.026 in the fully adjusted model, indicating that sex indeed influenced the effect of CMV-seropositivity. We subsequently stratified the model by sex. In the stratified but unadjusted model the mean cfPWV was 0.046 log10-units higher for CMV+ versus CMV- men (95% CI 0.001, 0.092; P = 0.046). In agreement with the observed median difference between these groups this translates into a difference of cfPWV of approximately 1.11 m/s (95% CI: 1.00 m/s to 1.24 m/s). The effect of CMV was slightly increased after adjusting for the demographic factors, age and socioeconomic standing (SES) (P = 0.016), and even stronger after additionally adjusting for smoking pack-years and waist-to-hip ratio (WHR). After further adjustment for lying systolic blood pressure (SBP) and the ratio of total cholesterol over HDL-cholesterol (TC/HDL-C), cfPWV was 0.059 log10-units higher in CMV+ compared to CMV- men (95% CI: 0.024, 0.093; P = 0.001) translating into a difference of cfPWV of about 1.13 m/s (95% CI: 1.06 m/s to 1.24 m/s). In contrast to this, a negative but not statistically significant association was observed among women. Cohort characteristics relevant to the linear regression models are shown in Table 1. The complete, fully adjusted model is shown in the supplementary data (Table S1). There were no significant differences between CMV+ and CMV- individuals with regard to blood pressure control (Table 1 and Table S2) or blood pressure medications (Table S3) neither in the entire cohort nor among men or women separately. As would be expected in this case, adjusting for the use of blood pressure medications made no tangible difference to the fully adjusted regression models (Table S4).

It is well known that CMV infection skews T-cell subset distribution towards an advanced memory phenotype and it has been reported that this happens more so in older men than in older women [6, 16]. Therefore, and because of the role of T-cells in cardiovascular disease it seemed pertinent to explore if the distribution of T-cell in terms of naïve and memory subsets in CMV+ men and women was reflective of the observed difference in cfPWV.
The proportions of memory T-cell subsets differ between CMV+ and CMV- individuals in both men and women

Whole blood T-cell phenotyping data was available for a sub-cohort of N = 123 individuals who also had valid cfPWV measurements. Characteristics of this sub-cohort are reported in supplementary Table S5 (parameters used in linear regression models), Table S6 (additional information on blood pressure and smoking), and Table S7 (medications). In this sub-cohort, the association of CMV serostatus with cfPWV in men shown in Table 2 remained significant at all levels of adjustment. We used the surface markers C-C chemokine receptor 7 (CCR7) and CD45RA to identify naïve T-cells (CCR7+CD45RA+, T_{NA}), as well as central memory (CCR7+CD45RA-, T_{CM}), effector memory (CCR7-CD45RA-, T_{EM}), and revertant memory T-cell subsets (CCR7-CD45RA+, T_{EMRA}), collectively referred to as T_{mem} (Figure S3) [29].

We examined CD4 and CD8 T-cell subset differences (i.e., relative population size) between CMV+ and CMV- individuals in the entire cohort but also separately among male and female participants, because CMV serostatus was associated with a difference in cfPWV in men but not women (Figure 1).

When comparing CMV+ to CMV- individuals, significant subset differences were found with regards to CD4 T_{NA} and CD4 T_{EMRA} (Figure 1A, top) and all CD8 subsets (Figure 1B, top). Upon stratification by sex these differences seemed to be stronger among men than women (relative difference of median subset size, only significant differences are listed). In CMV+ compared to CMV- men, CD4 T_{NA} were 30.5% lower (P = 0.004), and CD4 T_{EMRA} 63.3% higher (P = 0.005) (Figure 1A, middle), CD8 T_{NA}, T_{CM}, and T_{EM} were 71.1% (P = 0.000), 51.2% (P = 0.000), and 19.4% (P = 0.015) lower, respectively, however, CD8 T_{EMRA} cells 77.8% higher (P = 0.000) (Figure 1B, middle). In CMV+ compared to CMV- women, CD4 T_{EMRA} cells were 40.1% higher (P = 0.003) (Figure 1A, bottom), CD8 T_{NA} were 39.5% lower (P = 0.013) and CD8 T_{EMRA} cells 96.6% higher (P = 0.000) (Figure 1B, bottom).

\[
\text{Figure 1}
\]
Figure 1. **Differential distribution of canonical memory T-cell subsets in different subgroups defined by CMV serostatus and sex.** A. Box plots show the distribution of CD4 T\textsubscript{NA}, T\textsubscript{CM}, T\textsubscript{EM}, and T\textsubscript{EMRA} subsets in CMV- and CMV+ individuals among the entire cohort (top), men (middle) and women (bottom). B. Box plots show the distribution of the corresponding CD8 T cell subsets in each group. Box plots show median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers (o) and extreme values (*). Significant differences are indicated by P-values.

Statistically significant differences between men and women regarding T\textsubscript{mem} subset distribution were observed in the entire cohort and among CMV+ individuals but not CMV- individuals (Figure S4). In CMV+ men CD4 T\textsubscript{NA} were 28.4% lower (P = 0.002) and CD8 T\textsubscript{NA} 66.1% (P = 0.001) lower than in CMV+ women (relative difference of median subset size).

The overall effect of CMV infection on the canonical memory T-cell subsets appeared to be well captured by either the size of the naïve subset (T\textsubscript{NA}) or the T\textsubscript{mem} Subset (T\textsubscript{CM}, T\textsubscript{EM}, and T\textsubscript{EMRA}). Since T\textsubscript{NA} and T\textsubscript{mem} subset sizes are reciprocal, only the size of the T\textsubscript{mem} subset was used for further analysis. Figure 2 summarizes the differences in CD4 and CD8 T\textsubscript{mem} subset size between CMV- and CMV+ individuals in the whole cohort, among men and women.

Figure 2

**Figure 2. The percentage of antigen-experienced CD4 T\textsubscript{mem} cells is higher in CMV+ than CMV- individuals among men but not women.** A. Box plots show the proportions of CD4 and CD8 T\textsubscript{mem} in the entire cohort (top), men (middle), and women (bottom). B. Box
plots show the proportions of CD4 and CD8 $T_{\text{mem}}$ in the entire cohort (top), CMV-individuals (middle), and CMV+ individuals (bottom). Box plots show median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers (o) and extreme values (*). Significant differences are indicated by P-values.

In the entire sub-cohort CD4 $T_{\text{mem}}$ were 15.7 % higher (P = 0.021) in CMV+ compared to CMV- individuals (relative median differences given) (Figure 2A, top). Among men the corresponding difference was 31.6% (P = 0.004) (Figure 2A middle), but among women only 1.9% (n.s.) (Figure 2A bottom), indicating a much stronger effect of CMV in men than in women. In the entire cohort CD8 $T_{\text{mem}}$ were 12.2% higher (P = 0.000) in CMV+ compared to CMV- individuals (Figure 2A, top) but the corresponding difference among men and women was very similar (12.0%, P = 0.000 and 10.4%, P = 0.013, respectively) (Figure 2A, middle and bottom).

When directly comparing the sexes among CMV+ people, the CD4 $T_{\text{mem}}$ subset was 27.9% bigger (relative median difference) in men than in women (P = 0.002, Figure 2B, bottom), however, the CD8 $T_{\text{mem}}$ population was only 9% larger in men than in women (P = 0.001).

We wondered therefore if the significant difference in CD4 $T_{\text{mem}}$ between CMV+ and CMV- men (which was not found in women) might explain the association between CMV serostatus and pulse wave velocity that we had observed in men (but not in women). In order to be sure that the difference in CD4 $T_{\text{mem}}$ was truly associated with CMV serostatus and not, for example age, we first tested the effect of potential confounders in a linear regression model (Table 3). The model was initially run on the entire sub-cohort and was adjusted for age, sex, SES, smoking, and WHR, but not for SBP and cholesterol, as these last two covariates have no known relationship with $T_{\text{mem}}$ subset distribution. To account for the observed sex differences revealed by our memory T-cell subset analysis, the model was subsequently stratified by sex, which confirmed a significant effect of CMV on CD4 $T_{\text{mem}}$ in men but not women. We also tested the effect of CMV serostatus on CD8 $T_{\text{mem}}$, which, as expected, was similar in both sexes and significant at all levels of adjustment (Table S8).

Antigen-experienced CD4 T-cells correlate positively with cfPWV in CMV+ but correlate negatively in CMV- older people

We next assessed whether the proportions of CD4 $T_{\text{mem}}$ were associated with cfPWV. Bivariate correlation analysis indicated that among CMV+ individuals CD4 $T_{\text{mem}}$ population size was moderately positively associated with cfPWV, but not in the whole cohort. Among CMV- individuals CD4 $T_{\text{mem}}$ population size was moderately negatively associated with cfPWV (Figure 3A). No significant correlation between the proportions of CD8 $T_{\text{mem}}$ and cfPWV was identified in the entire cohort or after stratification by CMV-status (Figure 3B). As expected in this cohort of over 60 year-olds, no significant changes in CD4 $T_{\text{mem}}$ or CD8 $T_{\text{mem}}$ were observed as a function of age (not shown).
The percentage of antigen-experienced CD4 T<sub>mem</sub>-cells correlates positively with cfPWV in CMV+ but correlates negatively in CMV- people. Scatterplots show the relationships between the percentage of antigen-experienced CD4 T<sub>mem</sub>-cells (A), or CD8 T-cells (B) and cfPWV. The entire cohort is shown on the left, CMV+ individuals in the middle, and CMV- individuals on the right. cfPWV was Log10-transformed to improve visualization. Regression lines denote the results of regression on T<sub>mem</sub>. The Pearson correlation coefficient (R) is shown with each regression line.

The association between CD4 T<sub>mem</sub> and cfPWV was confirmed in a linear regression model (Table 4). The model was run in the entire sub-cohort as well as after stratification by CMV status based on the differences observed between CMV+ and CMV- people. Adjustment for covariates in this model was analogous to the first model testing the effect of CMV on cfPWV. As expected, in the whole cohort, no significant effect of CD4 T<sub>mem</sub> on cfPWV was identified, neither crude nor after adjustment for CMV or at any further level of adjustment (models 2-5). Splitting the model by CMV serostatus (in analogy to Figure 3) identified a statistically significant positive association between CD4 T<sub>mem</sub> and cfPWV among CMV+ people but a significant negative association among CMV- people. However, following adjustment, the positive association among those who were CMV+ remained significant but the beta regression coefficient was somewhat reduced from 0.249 (unadjusted) to 0.181 (fully adjusted). Since both cfPWV and T<sub>mem</sub> were log transformed for inclusion in the model, the beta coefficients in Table 4 are given in log units as well. A beta of 0.181 for CMV+ people (fully adjusted model) translates into an approximate increase of 0.3 m/s of cfPWV for every 10% increase of CD4 T<sub>mem</sub>. This clearly is a sizeable effect (Compare Figure 3, which corresponds to the unadjusted model). The negative association between CD4 T<sub>mem</sub> and cfPWV among CMV- individuals lost significance following adjustment. In order to avoid collinearity, these models were not adjusted for sex, since the effect of sex is at
least partially accounted for by the difference in size of the CD4 and CD8 T\textsubscript{mem} populations between men and women.

\textbf{CD28\textsuperscript{null} T-cell subset size is not significantly associated with cfPWV}

As a T-cell subset of particular interest, CD28\textsuperscript{null} T-cells are implicated in vascular damage and particularly in destabilizing atherosclerotic plaques [30]. CD4 CD28\textsuperscript{null} T-cells are strongly associated with CMV infection, with many actually being CMV-specific and occurring only in small frequencies in CMV- individuals [31]. CD28\textsuperscript{null} T-cells were gated as CD3+/CD8+ or CD4+/CD28\textsuperscript{null}/CD27- [31]. While no significant correlation was observed between CD28\textsuperscript{null} T-cells and T\textsubscript{mem} among CMV- individuals (CD28\textsuperscript{null} CD4 T-cell proportions were very low among CMV- people), the correlation was moderate among CMV+ individuals (\textbf{Figure 4A}). However, there was no significant correlation between CD4 or CD8 CD28\textsuperscript{null} T-cells and cfPWV, neither among CMV- nor among CMV+ individuals (\textbf{Figure 4B}). Because no meaningful association between CD28\textsuperscript{null} T-cells and cfPWV was suggested by the data, their role in causing increased cfPWV was not explored further.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{The proportions of CD4 and CD8 CD28\textsuperscript{null} T-cells show a moderate correlation with T\textsubscript{mem} among CMV+ people but do not correlate with cfPWV. CD28\textsuperscript{null} T-cells were measured by flow-cytometry (gated as CD28\textsuperscript{null}/CD27- T-cells). A. Correlations between CD28\textsuperscript{null} CD4 (top) and CD8 (bottom) T-cells and T\textsubscript{mem} are shown separately for CMV+ and CMV- people. B. Correlations between CD28\textsuperscript{null} CD4 (top) and CD8 (bottom) T-cells and cfPWV. Regression lines denote the results of regression on T\textsubscript{mem} or CD28\textsuperscript{null} T-cells. The Pearson correlation coefficient (R) is shown with each regression line.}
\end{figure}
**CMV-specific T-cells are not directly associated with cfPWV**

We also examined if the number of CMV-specific CD4 or CD8 T-cells were associated with cfPWV (the analysis being obviously limited to CMV+ individuals). These cells are known to predominantly have an advanced memory phenotype [32]. We measured activated CMV-specific CD4 and CD8 T-cells following stimulation of fresh PBMC with CMV protein-spanning peptide pools [33, 34]. The proteins for stimulation were selected from a panel of 19 proteins that had been found to be representative of all CMV T-cell target antigens in a mixed ethnicity population [35]. However, 3 proteins against which we had not detected a single response in White British people in a recent study were left out [9, 10]. The remaining 16 proteins were arranged in 14 stimulation pools (Table 5). Intracellular Interleukin-2 (IL-2), Tumor-necrosis factor (TNF), and Interferon-gamma (IFN-γ) were used separately or in combination to identify activated cells and the sum of the responses to all pools was used as a compound measure of T-cell responsiveness [35]. This avoids the significant bias introduced by measuring responses to single proteins [36]. Complete measurements were available for 69 CMV+ individuals who also had valid cfPWV measurements (33 male and 36 female). Figure S5 shows the distribution of CD4 and CD8 T-cell responsiveness (i.e., presence or absence of a response) across the tested peptide pools in our study.

Bivariate correlation analysis did not identify significant associations between the percentages of CMV-specific CD4 or CD8 T-cells and cfPWV (Figure 5A and B) for any of the individual stimulation pools (not shown). No further analyses were carried out to test associations between CMV-specific T-cells and cfPWV.

**Figure 5:** The frequencies of CMV-specific CD4 and CD8 T-cells do not correlate with cfPWV. Responses were measured by intracellular cytokine staining following stimulation of
fresh PBMC with 16 CMV protein-spanning peptide pools arranged in 14 stimulation pools. For each protein the percentage of cells expressing each activation marker (IL-2, TNF, or IFN-γ) or at least one of them was determined. The summated responses across all 14 CMV-peptide stimulation pools are plotted against cfPWV. Response size was determined based on the presence of at least one activation marker (A) or (the usually dominant) IFN-γ only (B).
Materials and methods

Ethics Statement
The study was approved by the UK National Research Ethics Service (NRES) ‘London Centre’ (Reference 13/LO/1270). Written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki.

Participants and samples
Participants were recruited through general practices (GP) in Southern England with help of the primary care research network (PCRN). Inclusion criteria were; White British ethnicity and age 60 years or older; exclusion criteria were; known immunodeficiency (including HIV infection), organ transplantation, use of immunosuppressive or immune-modulating drugs within the last year (excluding acetylsalicylic acid ≤ 100 mg/day), cancer or treatment for cancer within the previous 5 years, insulin dependent diabetes, moderate or advanced renal failure, liver disease, endocrine disorders (except corrected thyroid dysfunction), manifest autoimmune disease, dementia/mental incompetence, known alcoholism or other drug abuse, acute infection or illness in the last 4 weeks, raised body temperature (> 37.5 °C), moderate or severe heart failure (NYHA III or IV), inability to lie flat. Individuals with typical, age-related cardiovascular morbidity were not excluded. A flow-chart outlining recruitment and response data is shown in Figure S1. Further details are available in the online supplement.

Participant data and sample collection
Information collected at the main appointment included demographic and lifestyle factors including a detailed smoking history and socioeconomic status (SES), prior medical history, and medications. All participants also underwent a physical examination. Additional measurements included height, weight, waist and hip circumference, body composition, blood pressure, and vascular stiffness. Blood samples were taken by peripheral venepuncture.

CMV Serology
CMV immunoglobulin G (IgG) serology (Architect CMV IgG, Abbot, Maidenhead, UK) was performed at the Brighton and Sussex University Hospital Trust (BSUHT) virology laboratory using the same routine assay as used for all hospital patients. Individuals whose serum samples exceeded the assay threshold for positive IgG are referred to as ‘CMV seropositive’ or ‘CMV-infected’.

Medications
A detailed medical history included all current medications. An overview of common medications is provided for the entire cohort (Table S3) and separately for the sub-cohort with T-cell phenotyping data (Table S7).

Smoking
A detailed smoking history was collected which accounted for all types of tobacco smoking. Smoking other than cigarettes was translated into cigarette equivalents as follows; large cigars (4), small cigars/cigarillos (2), self-rolled cigarettes (1), pipes per bowl (1.5) [37]. The smoking history was represented by (cigarette) pack-years. Separate periods of smoking interrupted by periods of non-smoking were summed to determine the total number of years that an individual had smoked in their lifetime. Additional information on smoking is provided in Table 1 and Table S2 for the entire cohort as well as Table S5 and Table S6 for the sub-cohort with phenotyping data.
**SES**

Participants were asked to report their last job title and a description. We used the UK National Statistics Socio-economic Classification 2010 [38] to generate job title codes. The ONS NS-SEC online coding tool [39] was then used to assign ‘analytic categories’ and ‘operational categories’ for each participant based on the job title code. This tool utilises the job title code and takes into account whether a person is self-employed or unemployed and if they have any supervisory roles. Ambiguous cases were assigned the highest of any possible codes. We used the operational category to represent SES in our analysis.

**PWV**

Assessment of carotid-to-femoral PWV (measured in m/s) was carried out using the Complior® system (Alam Medical, Paris, France) at room temperature with the patient supine and after 10 minutes of resting. Patients had been asked to refrain from smoking, eating or drinking caffeinated drinks for 3 hours and drinking alcohol for 10 hours before measurements. Please find additional details in the online supplement.

**Resting blood pressure**

Resting blood pressure was measured in duplicate using standardised BP monitors (OMRON705-IT, Omron Electronics Ltd., Milton-Keynes, UK).

**Laboratory evaluation of blood samples**

Participant samples were treated like routine clinical samples and sent to the BSUHT pathology laboratory immediately after venepuncture. Analysis included routine full blood counts and fasting lipid profiles (total cholesterol, HDL cholesterol, triglyceride, TC/HDL ratio, non-HDL cholesterol).

**Whole blood T-cell phenotyping**

Fresh whole blood was stained with fluorescence-labelled monoclonal antibodies: CD45, CD3, CD4, CD8, CCR7, CD45RA, in a routine ‘lyse and wash’ protocol (for details see online supplement).

**CMV peptides**

Overlapping peptide pools representing 16 CMV different proteins arranged in 14 pools were used in T-cell stimulation assays (for details see online supplement).

**CMV reactivity of T-cells**

Freshly obtained PBMCs from CMV+ individuals were stimulated overnight (16 h) with overlapping CMV protein spanning peptide pools and subsequently stained and acquired by flow-cytometry. Surface markers included CD3, CD4, CD8, CD45RA, CCR7. Intracellular markers included IL-2, TNF, and IFN-γ (activation markers). The gating strategy is shown in Figure S6. Based on the positive control stimulation (SEB) a ‘response region’ was defined in a given plot (e.g., CD4 versus IFN-γ) in which cytokine positive events (IFN-γ in the example) were located. A positive cytokine response following stimulation with peptide pools was then identified in an analogous plot as a clustered population of activated cells displaying the activation marker in question (i.e. IFN-γ in the example) provided that (i) the clustered population of activated events occurred in the response region, and (ii) the cluster of activated cells comprised at least 0.01% of the reference population (CD4 or CD8 T-cells) after subtracting the corresponding percentage of cytokine positive events found in the same region in an unstimulated sample (negative control).
**Statistical analysis**
Statistical analysis was carried out using the SPSS 25 software package (IBM, London, UK). Our entire analytic sample (cohort) of N = 136 participants contained only individuals with valid cfPWV measurements who also had complete medical histories/data for all parameters of interest (hip and waist circumference, pack-year smoking history; socioeconomic status, pulse pressure, total and HDL cholesterol). Whole blood T-cell phenotyping was further available for a sub-cohort of N = 123 individuals. Non-parametric tests (Mann-Whitney U Test) were used to compare cfPWV and T-cell subset sizes between groups of individuals. Linear regression models were built to examine the association between CMV serostatus and PWV. For use in such models a number of parameters were log-transformed to improve normality, e.g., cfPWV and systolic blood pressure. Additional details of the statistical procedures are provided in the online supplement.
Discussion

Our main aim was to investigate whether CMV infection (i.e., positive IgG serostatus) is associated with increased central aortic stiffness in generally healthy people over 60 years of age. Importantly, we identified a positive association of CMV serostatus with increased cfPWV among men indicating an increase in CVD risk [19, 28]. Because of the known associations of (i) CMV infection with \( T_{\text{mem}} \) expansions [32] and (ii) \( T_{\text{mem}} \) subsets with atherosclerosis [7, 8] we examined if \( T_{\text{mem}} \) subset size and distribution in our cohort differed between CMV+ and CMV- individuals among men and women and might be associated with the difference in cfPWV that we had observed between CMV+ and CMV- men. Indeed, significant differences in \( T_{\text{mem}} \) population distribution between CMV+ and CMV- individuals were only found among men, which raised the question of whether \( T_{\text{mem}} \) cells are associated with increased cfPWV and so could help explain the differential effect of CMV on cfPWV in men and women.

Whereas in the whole cohort no correlation between CD4 or CD8 \( T_{\text{mem}} \) subset size and cfPWV was identified, a positive correlation between CD4 \( T_{\text{mem}} \) and cfPWV was seen among CMV+ people but a negative correlation between these parameters was found in CMV- people. Linear regression confirmed a significant positive association between CD4 \( T_{\text{mem}} \) population size and cfPWV in CMV+ individuals at all levels of adjustment, however, the negative association between the same parameters among CMV- individuals was lost. Meanwhile, regarding CD8 \( T_{\text{mem}} \) population size there was still no significant association with cfPWV after stratifying by CMV serostatus.

Prompted by published work [40, 41] and the known, close link between CMV infection and the proportions of CD28\(^{\text{null}} \) T-cells [30, 31] we also examined correlations between CD28\(^{\text{null}} \) T-cell population size and cfPWV. We were, however, unable to confirm a significant effect of CD28\(^{\text{null}} \) CD4 or CD8 T-cells on cfPWV. Since a CMV-associated effect of T-cells on cfPWV could also be mediated by CMV-specific T-cells, we additionally tested associations between CMV-specific CD4 or CD8 T-cells and cfPWV but no significant association was elucidated either.

Our results therefore show that (i) CMV infection is associated with statistically significant increases in cfPWV and CD4 \( T_{\text{mem}} \) in older men but not women, (ii) that CMV is linked to larger increases in CD4 \( T_{\text{mem}} \) in men than in women, and (iii) that the proportions of CD4 \( T_{\text{mem}} \) have a moderate but statistically significant positive association with cfPWV among CMV+ individuals. This raises the possibility that the effect of CMV infection on cfPWV is at least partly mediated by CD4 \( T_{\text{mem}} \) and observable in men but not women because upon CMV infection CD4 \( T_{\text{mem}} \) do not increase to the same extent in women as in men.

To our knowledge, sex as a possible modifier of the association of CMV with increased CVD risk has never been reported nor specifically investigated. For example, a very recent analysis of five longitudinal older cohorts concluded that CMV infection is not associated with all-cause or cardiovascular mortality in community-dwelling older adults [42]. However, authors did not consider the possibility of differential effects of CMV in men and women, different proportions of cardiovascular mortality in community-dwelling older adults [43] suggested that being CMV+ might have a protective effect in older women with regards to all-cause mortality at 3.3 years. The mechanism behind this effect has so far remained unclear but its presence appears to confirm an important difference in how male and female immune
systems handle this virus. Identifying and understanding sex-specific pathology therefore is extremely important in order to allow proper tailoring of preventative and therapeutic strategies according to sex. There are many examples of sex differences with regards to disease susceptibility and outcomes in particular in the field of autoimmunity and inflammation [44]. Immune system differences between the biological sexes are plentiful and may be mediated by sex hormones, however, often persist beyond the menopause [45-47].

Data from mouse models have confirmed sex differences in the way CMV affects the immune system by showing that male mice produce more inflammation in response to murine CMV (MCMV) infection than female mice. This seems to be related to higher expression of Toll-Like-Receptor 9 (TLR9) in males [48]. Higher expression of TLR9 results in a stronger innate and adaptive immune response against MCMV, which drives advanced T-cell differentiation. If the same is true in humans, men will produce more inflammation in response to CMV infection than women, contributing to increased numbers of memory T-cells and increased vascular damage in later life.

With regard to vascular damage in the context of CMV infection it is important to consider that EC are a primary target tissue of CMV infection. CMV-specific CD4 memory T-cells can damage and infiltrate infected endothelium because they display a highly differentiated memory phenotype with increased secretion of pro-inflammatory cytokines [13, 14]. Changes induced by endothelial inflammation include the upregulation of adhesion molecules, which, importantly, will also allow non-CMV-specific CD4 T-cells to infiltrate these areas, since adhesion molecules do not discriminate between T-cells of different antigen-specificity. In that sense, CMV-infection/CMV-specific T-cells may act as enablers allowing large numbers of activated memory/effector T-cells with a wide spectrum of antigen-specificities to infiltrate the vasculature [49]. By virtue of unspecific by-stander activation these might contribute to vascular inflammation, sclerosis and, ultimately reduced elasticity. This could explain the observed positive association of CD4 Tmed with increased cfPWV in CMV+ people observed in our study.

The CD28null subset of Tmed has attracted particular interest in the field of atherosclerosis, in particular coronary artery disease [30, 31]. However, we were unable to identify an association between CD28null T-cells and cfPWV despite the fact that an association of CD4 CD28null T-cells with cfPWV was previously reported in patients with ANCA-associated vasculitis (AAV) [41]. It is possible that the presence of autoimmune disease is an important amplifier of this association [50].

Regarding the role of CMV-specific T-cells, the CMV-specific portion of the entire T-cell repertoire is such as very difficult to quantify. It would essentially require testing responses against all potential CMV T-cell targets [35]. Using the summed response to a range of peptide pools representing the most frequently recognized CMV-proteins (as in the present study) is far better than focusing on single or just a few proteins [35, 36], however, still does not mean that CMV-specific T-cell immunity was captured in a representative way. This could be one reason why the size of the CMV-specific T-cell response was not associated with cfPWV in our study. However, given that not even a weak association was found a more plausible explanation might be that, as discussed above, CMV infection and CMV-specific T-cells only initiate the process of vascular infiltration by other effector/memory T-cells but that CMV-specific T-cells do not themselves cause most of the damage. Interestingly, others have reported a positive correlation between the proportions of CD8 T-cells recognizing the CMV UL83 protein and PWV in a cohort of N = 123 CMV+ Korean individuals (including patients with hypertension, coronary artery disease, diabetes mellitus, and healthy subjects), however, this association was much weaker still than the one we found between CD4 Tmed and cfPWV [40]. Based on the available data it would appear therefore that the direct contribution of CMV-specific T-cells to vascular stiffness is small.
Our study may be limited somewhat by a low participant response rate to the invitation which could affect the generalizability of our results to a degree. The reasons for this low rate of response potentially included the need to be fasting on arrival, the advised duration of the appointment of several hours, and the necessary travel to the investigation unit. These requirements might have biased the study in such a way that fitter individuals were more likely to self-select for participation. The fact that (i) we instructed GP practices to recruit generally healthy individuals and (ii) CMV status was unknown largely avoided any referral bias with respect to the presence of CMV-associated pathology or vascular changes. However, since in older people CMV infection has been associated with frailty [51] and chronic conditions for which individuals were excluded (such as insulin-dependent diabetes) [52], CMV+ individuals, in particular, might have been less likely to participate. However, such an effect would probably have biased the results against the detected association because frailty is itself associated with higher aortic pulse wave velocity [53] and so is diabetes at older ages [54]. The percentage of CMV seropositive individuals in the study (54%) was marginally below but very close to the published CMV prevalence in the UK among 40-79 year-olds (59%) [55] and cfPWV measured in our study matched published normal values very closely [28]. The slightly lower than expected seroprevalence was in line with our previous study in healthy older people in the same region of the UK [10] and, given that CMV infection is associated with a range of morbidities, especially at older ages [4, 51, 52], was probably the result of selecting older participants that were generally fit and well.

It was part of the study design to include only White British people in order to avoid differences in genetic background between CMV+ and CMV- participants affecting the results. This is a limitation with regards to generalizing our results to other ethnic groups and future confirmatory studies should include people of diverse biogeographical ancestry, however, these will have to be by orders of magnitude larger.

Conclusions

In conclusion, an association of CMV infection with increased central aortic PWV in generally healthy, White British older males is an alarming finding. If this association extends to healthy older men in general it would represent a significant global health issue, given that CMV prevalence is as high or higher than 90% in large parts of the world [26]. In order to address this problem, specific preventative strategies may be needed to mitigate the additional CVD risk of CMV+ males. This might involve strategies to prevent CMV-driven CD4 T_mem expansion, for example. It was previously shown in mice that treatment with Valaciclovir can reverse MCMV-specific CD8 T-cell expansion [56]. Whether a similar approach would work for CD4 T-cells and in humans has yet to be established. Another potentially interesting agent could be Rapamycin, a safe and widely used immuno-modulatory drug that was recently shown to have anti-aging properties, enhance immune function and reduce infections and inflammation in older people [57, 58] but also to possess anti-CMV activity [59]. In order to be able to develop the best therapeutic strategies in future, it is paramount that awareness of the health risks associated with chronic CMV infection increases among scientists and physicians. Further studies should be conducted to confirm our findings and identify the most suitable therapeutic targets in this complex interplay of CMV infection and the (aging) immune system.
Abbreviations: cfPWV: carotid-to-femoral pulse wave velocity, CMV: cytomegalovirus; CVD: cardiovascular disease; IQR: Interquartile range, SES: socioeconomic status, TC/HDL-C: ratio of total cholesterol over high-density lipoprotein (HDL) cholesterol, T\textsubscript{mem}: memory T cells, WHR: waist-to-hip ratio

Acknowledgments: We would like to thank all involved staff of the Clinical Investigation and Research Unit (CIRU) of Brighton and Sussex University Hospital Trust (BSUHT) for their continuous support. We are grateful to all participating GP practices and especially grateful to all participating volunteers. We would also like to thank the Primary Care Research Network (PCRN) South-East for coordinating the recruitment process.

Funding: This work was supported by The Dunhill Medical Trust, grant number R278/0213. AP is receiving funding from Miguel Servet CP19/00008, Instituto de Salud Carlos III & ERDF/ESF.

Competing interests: Frances Kirkham, Aalia Bano, Amanda M. Simanek, Alejandra Pera, Bernhard Reus, Stefano Caserta, Helen E Smith, Kevin A Davies, Chakravarthi Rajkumar, have no disclosures to make/declare no conflict of interest. Florian Kern is co-inventor and co-owner of a patent describing the use of protein-spanning, overlapping peptide pools for detecting antigen-specific T-cells as applied in this study (WO2001063286A2).
References

1. Wang H, Peng G, Bai J, He B, Huang K, Hu X, et al. Cytomegalovirus Infection and Relative Risk of Cardiovascular Disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): A Meta-Analysis of Prospective Studies Up to 2016. J Am Heart Assoc. 2017; 6.

2. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation. 1996; 94: 922-7.

3. Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009; 5: e1000427.

4. Firth C, Harrison R, Ritchie S, Wardlaw J, Ferro CJ, Starr JM, et al. Cytomegalovirus infection is associated with an increase in systolic blood pressure in older individuals. QJM. 2016; 109: 595-600.

5. Wertheimer AM, Bennett MS, Park B, Uhrlaub JL, Martinez C, Pulko V, et al. Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J Immunol. 2014; 192: 2143-55.

6. Di Benedetto S, Derhovanessian E, Steinhagen-Thiessen E, Goldeck D, Muller L, Pawelec G. Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. Biogerontology. 2015.

7. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020; 17: 387-401.

8. Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2015; 179: 173-87.

9. Bajwa M, Vita S, Vescovini R, Larsen M, Sansoni P, Terrazzini N, et al. Functional Diversity of Cytomegalovirus-Specific T Cells Is Maintained in Older People and Significantly Associated With Protein Specificity and Response Size. J Infect Dis. 2016; 214: 1430-7.

10. Bajwa M, Vita S, Vescovini R, Larsen M, Sansoni P, Terrazzini N, et al. CMV-Specific T-cell Responses at Older Ages: Broad Responses With a Large Central Memory Component May Be Key to Long-term Survival. J Infect Dis. 2017; 215: 1212-20.

11. Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A, et al. Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses. J Virol. 2012; 86: 1001-9.

12. Ho DD, Rota TR, Andrews CA, Hirsch MS. Replication of human cytomegalovirus in endothelial cells. J Infect Dis. 1984; 150: 956-7.

13. Pachnio A, Ciaurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016; 12: e1005832.

14. van de Berg PJ, Yong SL, Remmerswaal EB, van Lier RA, ten Berge IJ. Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol. 2012; 19: 772-9.

15. Zhou YF, Shou M, Guetta E, Guzman R, Unger EF, Yu ZX, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation. 1999; 100: 1569-75.

16. van der Heiden M, van Zelm MC, Bartol SJW, de Rond LGH, Berbers GAM, Boots AMH, et al. Differential effects of Cytomegalovirus carriage on the immune phenotype of middle-aged males and females. Sci Rep. 2016; 6: 26892.

17. Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Glob Health. 2017; 2: e000298.

18. Vrijenhoek JE, Den Ruijter HM, De Borst GJ, de Kleijn DP, De Vries JP, Bots ML, et al. Sex is associated with the presence of atherosclerotic plaque hemorrhage and modifies the relation between plaque hemorrhage and cardiovascular outcome. Stroke. 2013; 44: 3318-23.
19. Bonarjee VVS. Arterial Stiffness: A Prognostic Marker in Coronary Heart Disease. Available Methods and Clinical Application. Front Cardiovasc Med. 2018; 5: 64.
20. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 1236-41.
21. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006; 113: 657-63.
22. Wall NA, Chue CD, Edwards NC, Pankhurst T, Harper L, Steeds RP, et al. Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease. PLoS One. 2013; 8: e55686.
23. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 11: e0158765.
24. Vyse AJ, Hesketh LM, Pebody RG. The burden of infection with cytomegalovirus in England and Wales: how many women are infected in pregnancy? Epidemiol Infect. 2009; 137: 526-33.
25. Hecker M, Qiu D, Marquardt K, Bein G, Hackstein H. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang. 2004; 86: 41-4.
26. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010; 20: 202-13.
27. Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect. 2009; 137: 58-65.
28. Reference Values for Arterial Stiffness C. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010; 31: 2338-50.
29. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401: 708-12.
30. Broadley I, Pera A, Morrow G, Davies KA, Kern F. Expansions of Cytotoxic CD4(+)CD28(-) T Cells Drive Excess Cardiovascular Mortality in Rheumatoid Arthritis and Other Chronic Inflammatory Conditions and Are Triggered by CMV Infection. Front Immunol. 2017; 8: 195.
31. Pera A, Caserta S, Albanese F, Blowers P, Morrow G, Terrazzini N, et al. CD28(null) proatherogenic CD4 T-cells explain the link between CMV infection and an increased risk of cardiovascular death. Theranostics. 2018; 8: 4509-19.
32. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during aging. Curr Opin Immunol. 2005; 17: 480-5.
33. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000; 30: 1676-82.
34. Maeccker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001; 255: 27-40.
35. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ructhi F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005; 202: 673-85.
36. Sylwester A, Nambari KZ, Caserta S, Klenerman P, Picker LJ, Kern F. A new perspective of the structural complexity of HCMV-specific T-cell responses. Mech Ageing Dev. 2016; 158: 14-22.
37. Boffetta P, Pershagen G, Jockel KH, Forastiere F, Gaborieau V, Heinrich J, et al. Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst. 1999; 91: 697-701.
38. Statistics OfN. The National Statistics Socio-economic Classification (NS-SEC). 2016.
39. Statistics OfN. National Statistics Socio-economic Classification (NS-SEC) Coding Tool. 2010.
40. Yu HT, Youn JC, Kim JH, Seong YJ, Park SH, Kim HC, et al. Arterial Stiffness Is Associated With Cytomegalovirus-Specific Senescent CD8(+) T Cells. J Am Heart Assoc. 2017; 6.
41. Chanouzas D, Sagmeister M, Dyall L, Sharp P, Powley L, Johal S, et al. The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. Arthritis Res Ther. 2018; 20: 194.
42. Chen S, Pawelec G, Trompet S, Goldeck D, Mortensen LH, Slagboom PE, et al. Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults. J Infect Dis. 2020.
43. Adriaensen W, Pawelec G, Vaes B, Hamprecht K, Derhovanessian E, van Pottelbergh G, et al. CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study. J Gerontol A Biol Sci Med Sci. 2017; 72: 1155-62.
44. Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front Immunol. 2018; 9: 2279.
45. Klein SL. Immune cells have sex and so should journal articles. Endocrinology. 2012; 153: 2544-50.
46. Gubbels Bupp MR, Potluri T, Fink AL, Klein SL. The Confluence of Sex Hormones and Aging on Immunity. Front Immunol. 2018; 9: 1269.
47. Regitz-Zagrosek V, Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease. Physiol Rev. 2017; 97: 1-37.
48. Traub S, Demaria O, Chasson L, Serra F, Desnues B, Alexopoulos L. Sex bias in susceptibility to MCMV infection: implication of TLR9. PLoS One. 2012; 7: e45171.
49. Carman CV, Martinelli R. T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity. Front Immunol. 2015; 6: 603.
50. Bano A, Pera A, Almoukayed A, Clarke THS, Kirmani S, Davies KA, et al. CD28 (null) CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection. F1000Res. 2019; 8.
51. Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol. 2010; 171: 1144-52.
52. Chen S, de Craen AJ, Raz Y, Derhovanessian E, Vossen AC, Westendorp RG, et al. Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. Immun Ageing. 2012; 9: 18.
53. Orkaby AR, Lunetta KL, Sun FJ, Driver JA, Benjamin EJ, Hamburg NM, et al. Cross-Sectional Association of Frailty and Arterial Stiffness in Community-Dwelling Older Adults: The Framingham Heart Study. J Gerontol A Biol Sci Med Sci. 2019; 74: 373-9.
54. Loehr LR, Meyer ML, Poon AK, Selvin E, Palta P, Tanaka H, et al. Prediabetes and Diabetes Are Associated With Arterial Stiffness in Older Adults: The ARIC Study. Am J Hypertens. 2016; 29: 1038-45.
55. Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort. Clin Infect Dis. 2013; 56: 1421-7.
56. Beswick M, Pachnio A, Lauder SN, Sweet C, Moss PA. Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection. J Virol. 2013; 87: 779-89.
57. Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018; 10.
58. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany N Y). 2019; 11: 8048-67.
59. Pinana JL, Perez-Pitarch A, Guglieri-Lopez B, Gimenez E, Hernandez-Boluda JC, Terol MJ, et al. Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. Am J Transplant. 2018; 18: 2885-94.
### Table 1. Characteristics used in linear regression models (entire study cohort)

|                  | All          | Male         | Female        |                  | CMV- (N = 60) | CMV+ (N = 76) | P      | CMV- (N = 36) | CMV+ (N = 36) | P      | CMV- (N = 24) | CMV+ (N = 40) | P      |
|------------------|--------------|--------------|---------------|-----------------|---------------|---------------|--------|---------------|---------------|--------|---------------|---------------|--------|
| **cfPWV (m/s)**  |              |              |               |                 | 9.2 (3.2)     | 9.4 (2.9)     | n.s.   | 9.0 (2.4)     | 10.1 (2.5)    | 0.022  | 9.7 (4.8)     | 8.9 (2.9)     | n.s.   |
| **median (IQR)** |              |              |               |                 |               |               |        |               |               |        |               |               |        |
| **Age years**    | 69.2 ± 7.4   | 70.2 ± 7.1   | n.s.          | 69.6 ± 7.6      | 70.7 ± 8.5    | n.s.          | 68.5 ± 7.2 | 69.7 ± 5.5    | n.s.          |        |               |               |        |
| **median (IQR)** | 4.3 (3.0)    | 5.5 (4.8)    | n.s.          | 4.1 (3.9)       | 6.0 (5.7)     | n.s.          | 5.5 (4.5) | 4.7 (3.1)     | n.s.          |        |               |               |        |
| **Smoking (pack-years)** | 0.5 (10.1)  | 0.2 (7.0)    | n.s.          | 0.3 (12.5)      | 2.4 (22.0)    | n.s.          | 0.6 (9.4) | 0.0 (3.2)     | n.s.          |        |               |               |        |
| **median (IQR)** | 1.0 ± 0.2    | 0.9 ± 0.1    | n.s.          | 1.0 ± 0.2       | 1.0 ± 0.1     | n.s.          | 0.9 ± 0.1 | 0.9 ± 0.1     | n.s.          |        |               |               |        |
| **TC/HDL-C**     | 3.3 ± 1.0    | 3.2 ± 0.8    | n.s.          | 3.6 ± 1.0       | 3.3 ± 0.8     | n.s.          | 3.0 ± 0.9 | 3.1 ± 0.8     | n.s.          |        |               |               |        |
| **median (IQR)** | 140 (21)     | 136 (27)     | n.s.          | 141 (22)        | 135 (27)      | n.s.          | 136 (26) | 130 (28)      | n.s.          |        |               |               |        |

SES: socioeconomic standing, WHR: waist over hip ratio, TC/HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure

*aParameters for which median (IQR) is provided were log-transformed for use in linear regression models*
Table 2. Association between cytomegalovirus serostatus and cfPWV among the entire cohort and among men and women separately

|                        | Beta coefficient (95% Confidence Interval)¹  |
|------------------------|---------------------------------------------|
|                        | Model 1ᵇ | Model 2ᶜ | Model 3ᵈ | Model 4ᵉ |
| CMV serostatus/all (N = 136) | -0.018 (-0.019, 0.056) | -0.011 (-0.022, 0.044) | 0.014 (-0.020, 0.047) | 0.021 (-0.008, 0.049)² |
| Model split by sex     |           |           |           |           |
| CMV serostatus/men (N = 72) | 0.046 (0.001, 0.092)* | 0.048 (0.008, 0.087)* | 0.055 (0.016, 0.094)** | 0.059 (0.024, 0.093)*** |
| CMV serostatus/women (N = 64) | -0.016 (-0.078, 0.046) | -0.027 (-0.081, 0.027) | -0.024 (-0.079, 0.031) | -0.010 (-0.055, 0.035)³ |

¹log10 units  
ᵇModel 1 unadjusted.  
ᶜModel 2 adjusted for age, socioeconomic status, and sex (entire cohort only).  
ᵈModel 3 additionally adjusted for smoking pack-years and WHR.  
ᵉModel 4 additionally adjusted for lying SBP and total TC/HDL-C.  
²R-squared of fully adjusted model: 0.474  
³R-squared of fully adjusted model: 0.550  
⁴R-squared of fully adjusted model: 0.554  
*P < 0.05; **P < 0.01

Table 3. Association between cytomegalovirus serostatus and CD4 Tₘₑₘ population size among the entire sub-cohort and among men and women separately

|                        | Beta coefficient (95% Confidence Interval)⁵  |
|------------------------|---------------------------------------------|
|                        | Model 1ᵇ | Model 2ᶜ | Model 3ᵈ |
| CMV serostatus/all (N = 123) | 0.048 (0.004, 0.092)* | 0.056 (0.013, 0.100)* | 0.053 (-0.009, 0.097)* |
| Model split by sex     |           |           |           |
| CMV serostatus/men (N = 66) | 0.079 (0.027, 0.132)** | 0.078 (0.024, 0.132)** | 0.073 (0.18, 0.128)* |
| CMV serostatus/women (N = 57) | 0.032 (-0.040, 0.104) | 0.034 (-0.039, 0.106) | 0.028 (-0.046, 0.101) |

⁵log10 units  
bModel 1 unadjusted.  
ᶜModel 2 adjusted for age, socioeconomic status, and sex (entire cohort only).  
ᵈModel 3 additionally adjusted for lying SBP and total TC/HDL-C.  
*P < 0.05; **P < 0.01
Table 4. Association between CD4 T\textsubscript{mem} and cfPWV among the entire sub-cohort and among CMV- and CMV+ participants separately

|                          | Model 1\textsuperscript{b} | Model 2\textsuperscript{c} | Model 3\textsuperscript{d} | Model 4\textsuperscript{e} | Model 5\textsuperscript{f} |
|--------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| CD4 T\textsubscript{mem}/all (N = 123) | 0.045 (-0.115, 0.205) | -0.035 (-0.128, 0.199) | 0.040 (-0.106, 0.187) | 0.046 (-0.100, 0.193) | 0.020 (-0.104, 0.144)* |
| CD4 T\textsubscript{mem}/CMV- (N = 51) | -0.289 (-0.561,-0.017)* | -0.143 (-0.391, 0.105) | -0.149 (-0.396, 0.099) | -0.116 (-0.337, 0.104)* |
| CD4 T\textsubscript{mem}/CMV+ (N = 72) | 0.249 (-0.057, 0.441)* | 0.206 (0.018, 0.394)* | 0.235(0.044, 0.425)* | 0.181 (0.027, 0.335)* |

\textsuperscript{a}log\textsubscript{10} units
\textsuperscript{b}Model 1 unadjusted.
\textsuperscript{c}Model 2 adjusted for CMV (unless stratified by CMV)
\textsuperscript{d}Model 3 additionally adjusted for age and socioeconomic status
\textsuperscript{e}Model 4 additionally adjusted for smoking pack-years and WHR.
\textsuperscript{f}Model 5 additionally adjusted for lying SBP and TC/HDL-C.
\textsuperscript{g}R\textsuperscript{-}squared of fully adjusted model: 0.472
\textsuperscript{h}R\textsuperscript{-}squared of fully adjusted model: 0.524
\textsuperscript{i}R\textsuperscript{-}squared of fully adjusted model: 0.528

\*P < 0.05; **P < 0.01.
| Pool | CMV Protein(s) | No. of Peptides |
|------|----------------|-----------------|
| 1    | UL55<sup>a</sup> | 224             |
| 2    | UL83           | 138             |
| 3    | UL86           | 340             |
| 4    | UL122          | 120             |
| 5    | UL123          | 143             |
| 6    | UL153          | 67              |
| 7    | UL32           | 260             |
| 8    | UL28           | 92              |
| 9    | UL48A<sup>a</sup> | 281         |
| 10   | UL48B<sup>b</sup> | 281         |
| 11   | US3            | 44              |
| 12   | UL151 & UL82   | 219 (82 & 137)  |
| 13   | UL94 & US29    | 197 (84 & 113)  |
| 14   | US24 & UL36    | 240 (123 & 117) |

<sup>a</sup>A panel of 19 CMV protein-spanning peptide pools was previously shown to correlate highly with the CD4 and CD8 T-cell response against 203 tested CMV proteins.[35] The original panel contained UL99, UL103, and US32 in addition, which had been used previously but were left out here since responses were absent in >100 White British people.

<sup>b</sup>UL48 was divided into two pools (UL48A and UL48B), however, results were combined
Supplementary Materials:

Materials and methods

Participants and samples
GPs were instructed to search their electronic patient records with respect to the study’s inclusion and exclusion criteria, compile a list of all potentially eligible participants, assign a number to each individual, and communicate the total number eligible to the PCRN. Over several recruitment waves the PCRN provided each practice with a list of random numbers. Larger practices were instructed to reach out to 100 individuals per wave and engaged in more waves than smaller practices, which were instructed to reach out to 50 individuals per wave. For each wave of invitations, new random numbers were sent to each practice (previously used numbers were excluded). Recruitment occurred in multiple waves over a total of 2.5 years. Practices mailed written invitations to all selected individuals. If interested, invited participants contacted the research nurse team at the Clinical Investigation and Research Unit (CIRU) of Brighton and Sussex University Hospital NHS Trust (BSUHT) to schedule an initial screening appointment, which took place in their GP’s practice. At this appointment, inclusion/exclusion criteria were double-checked, written informed consent was obtained from eligible participants, a blood sample was obtained by venepuncture for testing CMV-serostatus, and participants were invited to attend the main study appointment at CIRU.

Participants from a previous study (N = 131) using the same random recruitment approach 3 years earlier, were invited as well (direct mail-out by CIRU). Respondents (N = 30) were invited directly for the main appointment after confirming eligibility via telephone. Their CMV status had previously been recorded but was not a criterion for selection.

At the main study appointment, eligibility of all participants was reviewed, a detailed medical history was obtained, vascular measurements were performed, and additional blood samples were taken for measuring blood counts, lipid values, and general blood biochemistry. Individuals were recruited in the order in which responses were received. Vascular laboratory staff were blinded to the CMV status of participants at all times. Recruitment was continued until N = 209 individuals had attended the main appointment. After reviewing eligibility according to the selection criteria N = 193 participants were eligible for assessment in the vascular lab (Figure S5). Of these, 104 were CMV+ and 89 were CMV-.
Briefly, with the patient in supine position the carotid and femoral arteries are located and the positions where carotid and femoral pressures are to be measured are marked. The distance between these points is measured and recorded in the analysis software. The sensors are positioned on the respective measurement points for data acquisition. During measurement, the time-delay between recording the pulse wave at the carotid and femoral arteries is recorded along with the changes in central and peripheral brachial blood pressure. The analysis software subsequently displays pulse wave velocity and the central (carotid) pressure waveform analysis. Measurement of cfPWV was attempted in 193 and completed in 181 individuals. In 12 individuals the procedure was aborted due to compliance issues. A total of N = 137 (76%) of cfPWV measurements passed quality control (QC) by two physicians blinded to the CMV infection status of participants. QC was based on the shape of the recordings and the consistency (wave form) of the ten consecutive waves. Extreme outliers in terms of cfPWV (> Q3+3*IQR; < Q1-3*IQR) were removed during analysis leaving N = 136 accepted measurements for cfPWV.

Whole blood antibody staining for T-cell phenotyping
Fresh, sodium-heparin-anticoagulated whole blood (100 μL) was incubated with monoclonal, fluorescence-labeled staining antibodies as follows. Anti-CD45-AlexaFluor (AF)700, anti-CD3-Pacific Blue (PB), anti-CD4-Brilliant Violet (BV)510, anti-CD8α-allophycocyanin (APC)-H7, anti-CCR7 BV605, anti-CD45RA-Fluorescein-thio-cyanate (FITC) (all BioLegend, Cambridge, UK). Cells were incubated for 20 min at RT in the dark followed by addition of BD lysis buffer (BD) and incubation for 10 min according to the manufacturer’s instructions. Samples were then centrifuged (5 min at 350g), resuspended in PBS and spun again (5 min at 350g). Finally, cells were fixed (1% paraformaldehyde in water) and washed. Pellets were resuspended in 300 μL of staining buffer (BD) prior to acquisition within 1-4 h.

CMV-peptides
Twenty-five μg per peptide per pool (PepMix™, JPT Peptide Technologies, Berlin, Germany) were dissolved in 100 μL of DMSO (Sigma-Aldrich, Gillingham, UK) (0.25 μg/μL). For T-cell stimulation assays 2 μL of the 0.25 μg/μL CMV-peptide solutions were used for a final concentration of 1 μg/mL per peptide. All assays included a positive control that consisted of 1 μg/ml (final concentration) of Staphylococcal enterotoxin B from Staphylococcus aureus (SEB,
Sigma) dissolved in DMSO, and a negative control consisting of 2 μL of DMSO alone (i.e., the peptide solvent). A list of all CMV proteins used in the study is provided in Table 5.

**CMV-reactivity of T-cells**

CMV-specific T-cells from CMV+ individuals were activated by incubating PBMC for 16 h overnight (37 °C, humidified 5% CO₂ atmosphere) with peptide pools, positive and negative controls. Per tube 1x10⁶ PBMCs were incubated with 2 μL of the corresponding CMV peptide pool, 1 μL of SEB solution (positive control, final concentration 1 μg/mL) or 2 μL of DMSO (negative control) in complete RPMI media (final incubation volume 250 μL). After 2 h in a standard incubator (37°C, humidified 5% CO2 atmosphere) each tube received 250 μL of complete RPMI containing 10 μg/mL of Brefeldin A (BFA), resulting in a final volume of 500 μL for the remaining incubation time (14 h). Thereafter each tube was incubated for 10 min at 37 °C (water bath) with 100 μL of 20 mM EDTA (Sigma). Subsequently, samples were washed with 3 mL of wash buffer (PBS with 0.5% w/v BSA and 0.1% w/v sodium azide, (Sigma) and centrifuged at 400g for 8 min at RT (‘wash step’). Samples were then surface-stained (30 min at 4 °C in the dark) with fluorochrome conjugated monoclonal antibodies including anti-CD3 Pacific Blue, anti-CD4 BV510, anti-CD8a PE-Cy7, anti-CCR7 BV605, and anti-CD45RA PerCP/Cy5.5 (all Biolegend), followed by a wash step. Following the surface stain 1ml of 1x BD ‘FACS Lysing Solution’ (BD) was added to each tube and tubes incubated for 10 min in the dark. Another wash step followed and subsequently, BD ‘Permeabilization solution 2’ was added to each tube and samples were incubated for 10 min in the dark. After a further wash step, cells were stained intracellularly with anti-IL-2 APC, anti-TNFα AF 700 and anti-IFN-γ FITC (all Biolegend) for 30 min at 4 °C in the dark followed by a wash step. Then, 1 mL of 0.5% paraformaldehyde (in water) was added to each tube and incubated in the dark for 5 min. After a final wash step cells were stored at 4 °C in the dark until acquisition.

**Data acquisition and analysis**

Samples were acquired on an LSR II flow-cytometer (BD). FlowJo v9.x software (Tree Star Inc., Ashland, OR) was used for data analysis. Gating strategy is described in Figure S6.

**Quality control for flow-cytometry**

Comparable day-to-day performance of the LSR II flow-cytometer was ascertained by running CS&T calibration beads (BD) on a daily basis. In addition, 8-peak Rainbow beads were used prior to every run in order to adjust PMTs in such a way that with respect to each detector,
every peak was always in the same channel.

Statistical analysis

Linear regression models were adjusted for covariates as follows.
(1) Linear regression models testing an association of CMV infection status (CMV+ or CMV-) with cfPWV. First, models were unadjusted. They were then adjusted for sex (total sample only), age, and SES. Next, they were adjusted smoking pack-years and WHR. Finally, models were adjusted for SBP and TC/HDL-C.
(2) Linear regression models testing an association of CMV infection status with T_{mem}. Initial models were unadjusted. Subsequent models were adjusted for age, SES, and sex (unless stratified by sex). They were then adjusted for smoking pack-years and WHR. Models were not adjusted for SBP and TC/HDL-C as no consistent effect of these parameters on T_{mem} is known.
(3) Linear regression models testing an association of T_{mem} with cfPWV. Initial models were unadjusted. Subsequent models were adjusted for CMV (unless stratified by CMV), and then age (unless stratified by age) and SES. Finally, models were adjusted for WHR and smoking pack-years. Finally, models were adjusted for SBP and TC/HDL-C. To avoid collinearity, these models were not adjusted for sex, because the effect of sex was already accounted for by the proportions of T_{mem} (which were higher in men than in women).

Data trends in scatter plots were visualised using the SPSS ‘fit line’ command (linear model). Bivariate correlations were tested using the ‘correlate’ command in SPSS, the Pearson Correlation Coefficient (R) is reported.
Supplementary Figures

**Figure S1.** Flowchart describing the recruitment of individuals for measuring PWV and other relevant parameters.
Figure S2. cfPWV is higher in CMV+ compared with CMV- older men. Diagrams show the distribution of cfPWV in men and women stratified by CMV infection status. Box plots show median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers (o) and extreme values (*). Significant differences are indicated by P-values.
Figure S3. Gating strategy for whole blood surface phenotyping. Lymphocytes were gated in an SSC/FSC plot. Singlets were gated in an FSC-A/FSC-H plot, doublets were excluded. From the singlet gate a CD3 T-cell gate was created in a CD3/CD8 fluorescence dot-plot (top right). A CD4 versus CD8 fluorescence dot plot allowed to visualize T-cell subsets based on CD4 and CD8 expression (middle). For the analysis of CCR7 and CD45RA expression CD4 T-cells (bottom left) and CD8 T-cells (bottom right) were gated separately. The canonical naïve (CCR7+CD45RA+, TNA), central memory (CCR7+CD45RA-, TCM), effector memory (CCR7-CD45RA-, TEM), and revertant memory T-cell subsets (CCR7-CD45RA+, TEMRA) were identified as shown. The same gating sequence and strategy was applied to all samples. The expression of CD28 was used to aid the discrimination between the subsets in that the CCR7+/CD45RA+ subset is CD28bright (not shown).
Figure S4. Differential distribution of canonical CD4 and CD8 memory T-cell subsets in men and women stratified by CMV status. A. Box plots show the distribution of CD4 T\textsubscript{NA}, T\textsubscript{CM}, T\textsubscript{EM}, and T\textsubscript{EMRA} subsets in men and women among the entire cohort (top), CMV-individuals (middle) and CMV+ individuals (bottom). B. Box plots show the distribution of the corresponding CD8 T cell subsets in each group. Box plots show median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ + 1.5*IQR), outliers (o) and extreme values (*). Significant differences are indicated by P-values.
**Figure S5**: Bar charts showing the distribution of CD4 (top) and CD8 (bottom) T-cell responsiveness to 16 different CMV proteins arranged in 14 stimulation pools. Each column represents the number of positive responses among CMV+ people to one stimulation pool. Positive responses were identified by intracellular cytokine staining following stimulation of fresh PBMC with protein-spanning peptide pools.
Figure S6. Gating strategy for ICS on antigen-stimulated, fresh PBMC. (1) Lymphocytes were gated in an SSC/FSC plot. (2) Singlets were gated in an FSC-A/FSC-H plot, and doublets were excluded. (3) From the singlet gate, two CD3 T-cell gates were created, one in a CD3/CD4 fluorescence dot-plot (top right) and one in a CD3/CD8 fluorescence dot-plot. Each gate allowed for inclusion of sometimes strongly TCR downregulated T-cells. (4) The two CD3 gates were then combined in a Boolean gate (OR) for gating CD4 and CD8 T-cells in a CD4 versus CD8 fluorescence dot plot, which allowed to visualize T-cell subsets based on CD4 and CD8 expression. (5) For the analysis of activated T-cells, CD4 and CD8 T-cells were plotted versus the activation markers (IL-2, TNF, and IFN-γ). These gates were overlaid with the canonical memory T-cell subsets defined by CCR7 and CD45RA expression. The same gating sequence and strategy was applied to all samples.
**Supplementary Tables**

**Table S1.** Association between cytomegalovirus serostatus and cfPWV among men and women separately, fully adjusted model

|                | Beta coefficient (95% Confidence Interval) | P value |
|----------------|--------------------------------------------|---------|
| **Men**        |                                            |         |
| CMV serostatus | 0.059 (0.024, 0.093)                        | 0.001   |
| Age            | 0.005 (0.003, 0.008)                        | 0.000   |
| SES            | -0.087 (-0.163, -0.012)                    | 0.024   |
| WHR            | 0.142 (0.017, 0.267)                        | 0.027   |
| Smoking pack-years | 0.000 (-0.006, -0.006)    | 0.961   |
| TC/HDL-C       | -0.006 (-0.026, 0.014)                     | 0.562   |
| SBP lying      | 0.732 (0.422, 1.041)                       | 0.001   |
| **Women**      |                                            |         |
| CMV serostatus | -0.010 (-0.055, 0.035)                     | 0.661   |
| Age            | 0.007 (0.003, 0.011)                        | 0.001   |
| SES            | 0.064 (-0.037, 0.165)                      | 0.212   |
| WHR            | -0.219 (-0.556, 0.118)                     | 0.198   |
| Smoking pack-years | 0.007 (0.000, 0.015)    | 0.060   |
| TC/HDL-C       | -0.004 (-0.024, 0.032)                     | 0.776   |
| SBP lying      | 1.000 (0.641, 1.359)                       | 0.000   |

SES: socioeconomic standing, WHR: waist over hip ratio, TC-HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure

*Log10 units

*R-squared of fully adjusted model: 0.550

*R-squared of fully adjusted model: 0.554
|                      | All (N = 60) | Male (N = 36) | Female (N = 40) | P  |
|----------------------|-------------|--------------|-----------------|----|
| CMV-                 |             |              |                 |    |
| CMV+                 |             |              |                 |    |
| DBP lying (mmHg)     | 76.8 (11.1) | 74.5 (14.5)  | n.s.            |    |
| median (IQR)         | 79.8 (9.1)  | 76.0 (19.3)  | n.s.            |    |
| PP lying (mmHg)      | 58.0 (18.9) | 57.2 (18.1)  | n.s.            |    |
| median (IQR)         | 57.5 (16.0) | 58.0 (15.4)  | n.s.            |    |
| Ever smoker N (%) in column | 32 (53.3)  | 43 (57.6)  | n.s.            |    |
| Current smoker N (%) in column | 6 (10.0)    | 5 (6.5)    | n.s.            |    |
| Time since smoking cessation in ex-smokers, mean ± STD | 31.7 ± 14.2 | 34.1 ± 13.2 | n.s. | 29.6 ± 14.5 | 31.0 ± 14.2 | n.s. | 34.0 ± 14.0 | 37.5 ± 11.5 | n.s. |

DBP = diastolic blood pressure, PP = pulse pressure
Table S3. Common medications\textsuperscript{a, b} (entire cohort)

|                          | All          | Female       |
|--------------------------|--------------|--------------|
|                          | CMV- (N = 60) | CMV+ (N = 76) | CMV- (N = 36) | CMV+ (N = 36) | N    | CMV- (N = 24) | CMV+ (N = 40) | N    | P   |
| Cholesterol lowering drugs (all) | 17 (28.3)    | 14 (18.4)   | n.s.         | 14 (38.9)    | 8 (22.2) | n.s.         | 3 (12.5)    | 6 (15.0) | n.s. |
| Statin                   | 16 (26.7)    | 14 (18.4)   | n.s.         | 13 (36.1)    | 8 (22.2) | n.s.         | 3 (12.5)    | 6 (15.0) | n.s. |
| Oral anti-hyperglycemic  | 3 (5.0)      | 0 (0.0)     | n.s.         | 1 (2.8)      | 0 (0.0)  | n.s.         | 2 (8.3)     | 0 (0.0)  | n.s. |
| Blood pressure lowering drugs (any) | 18 (30) | 22 (28.9)   | n.s.         | 11 (30.6)    | 9 (25.0) | n.s.         | 7 (29.2)    | 13 (32.5) | n.s. |
| Blood pressure lowering drugs (number) | 0.43 ± 0.77 | 0.49 ± 0.92 | n.s.         | 0.44± 0.77   | 0.47± 0.97 | n.s.         | 0.42± 0.77  | 0.50± 0.87 | n.s. |
| Mean± STD               | 0.49 ± 0.77  | 0.49 ± 0.92 | n.s.         | 0.47± 0.97   | 0.50± 0.87 | n.s.         | 0.50± 0.87  | n.s.     |      |
| Diuretic                | 3 (5.0)      | 8 (10.5)    | n.s.         | 1 (2.8)      | 3 (8.3)  | n.s.         | 2 (8.3)     | 5 (12.5) | n.s. |
| Beta-blocker            | 8 (13.3)     | 5 (6.6)     | n.s.         | 5 (13.9)     | 2 (5.6)  | n.s.         | 3 (12.5)    | 3 (7.5)  | n.s. |
| Ca-antagonist           | 6 (10.0)     | 5 (6.6)     | n.s.         | 4 (11.1)     | 3 (8.3)  | n.s.         | 2 (8.3)     | 2 (5.0)  | n.s. |
| ACE inhibitor/AT-II receptor antagonist | 12 (20) | 16 (21.1)   | n.s.         | 8 (22.2)     | 7 (19.4) | n.s.         | 4 (16.7)    | 9 (22.5) | n.s. |
| Centrally acting anti-hypertensive | 0 (0.0) | 1 (1.3)    | n.s.         | 0 (0.0)      | 1 (2.8)  | n.s.         | 0 (0.0)     | 0 (0.0)  | n.s. |
| Nitroglycerine          | 0 (0.0)      | 0 (0.0)     | n.s.         | 0 (0.0)      | 0 (0.0)  | n.s.         | 0 (0.0)     | 0 (0.0)  | n.s. |
| Platelet aggregation inhibitor | 6 (10.0) | 9 (11.8)   | n.s.         | 5 (13.9)     | 7 (19.4) | n.s.         | 1 (4.2)     | 2 (5.0)  | n.s. |

\textsuperscript{a}Medications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers.

\textsuperscript{b}Unless indicated otherwise, values are reported as N (% of group in column)
Table S4. Association between cytomegalovirus serostatus and cfPWV among the entire cohort and among men and women separately

|                        | Model 4A^b | Model 4B^c |
|------------------------|------------|------------|
| CMV serostatus/all (N = 136) | 0.021 (-0.008, 0.049) | 0.022 (-0.006, 0.050) |
| Models split by gender: |            |            |
| CMV serostatus/men (N = 72)   | 0.059 (0.024, 0.093)** | 0.059 (0.024, 0.094)** |
| CMV serostatus/women (N = 64) | -0.011 (-0.056, 0.035) | -0.011 (-0.056, 0.033) |

^dlog10 units
^bModel 4A corresponds to Model 4 in Table 2, additionally adjusted for the number of anti-hypertensive medications taken.
^cModel 4B corresponds to Model 4 in Table 2, additionally adjusted for presence/absence of antihypertensive medication (yes/no)
*P < 0.05; **P < 0.01
**Table S5.** Characteristics used in linear regression models (sub-cohort with T-cell phenotyping data)

|                      | All          | Male         | Female        |   |
|----------------------|--------------|--------------|---------------|---|
|                      | CMV- (N = 51) | CMV+ (N = 72) | P             | CMV- (N = 32) | CMV+ (N = 34) | P             | CMV- (N = 19) | CMV+ (N = 38) | P             |
| **PWV (m/s)**        |              |              |               |              |              |               |              |              |               |              |
| median (IQR)         | 9.5 (3.4)    | 9.4 (3.0)    | n.s.          | 8.9 (2.9)    | 10.1 (2.5)   | 0.029         | 9.8 (4.3)    | 8.9 (3.3)    | n.s.          |
| **Age years**        |              |              |               |              |              |               |              |              |               |              |
| mean ± STD           | 69.1 ± 7.4   | 70.4 ± 7.2   | n.s.          | 69.7 ± 7.8   | 71.0 ± 8.7   | n.s.          | 68.1 ± 6.8   | 69.8 ± 5.6   | n.s.          |
| **SES**              |              |              |               |              |              |               |              |              |               |              |
| median (IQR)         | 4.3 (3.9)    | 6.0 (4.8)    | n.s.          | 4.2 (3.9)    | 6.0 (5.2)    | n.s.          | 5.0 (3.0)    | 4.7 (3.1)    | n.s.          |
| **Smoking (pack-years)** |            |              |               |              |              |               |              |              |               |              |
| median (IQR)         | 0.5 (13.0)   | 0.1 (6.8)    | n.s.          | 1.3 (12.5)   | 1.1 (23.1)   | n.s.          | 0.5 (15.0)   | 0.0 (3.2)    | n.s.          |
| **WHR**              |              |              |               |              |              |               |              |              |               |              |
| mean ± STD           | 1.0 ± 0.2    | 0.9 ± 0.1    | n.s.          | 1.0 ± 0.20   | 1.0 ± 0.1    | n.s.          | 0.9 ± 0.0    | 0.9 ± 0.1    | n.s.          |
| **TC/HDL-C**         |              |              |               |              |              |               |              |              |               |              |
| mean ± STD           | 3.4 ± 0.9    | 3.2 ± 0.8    | n.s.          | 3.5 ± 0.9    | 3.3 ± 0.8    | n.s.          | 3.1 ± 1.0    | 3.0 ± 0.8    | n.s.          |
| **SBP lying (mmHg)** |              |              |               |              |              |               |              |              |               |              |
| median (IQR)         | 142 (18)     | 135 (26)     | n.s            | 141 (16)     | 137 (24)     | n.s            | 142 (25)     | 131 (28)     | n.s            |

SES: socioeconomic standing, WHR: waist over hip ratio, TC/HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure

*aParameters for which median (IQR) is provided were log-transformed for use in linear regression models*
Table S6. Additional information on smoking and blood pressure (sub-cohort with T-cell phenotyping data)

|                          | All (N=51) | CMV+ (N=72) | P   | CMV- (N=32) | CMV+ (N=34) | P   | CMV- (N=19) | CMV+ (N=38) | P   |
|--------------------------|------------|-------------|-----|-------------|-------------|-----|-------------|-------------|-----|
| DBP lying (mmHg) median (IQR) | 77.5 (10.0) | 74.8 (14.8) | n.s. | 80.3 (9.0)  | 77.0 (20.1) | n.s. | 74.5 (10.0) | 73.8 (14.1) | n.s. |
| PP lying (mmHg) median (IQR) | 58.5 (18.5) | 57.3 (18.1) | n.s. | 57.5 (12.9) | 58.8 (14.4) | n.s. | 68.5 (21.5) | 54.0 (23.1) | n.s. |
| Ever smoker N (% in column) | 28 (55.0)  | 39 (54.1)  | n.s. | 18 (56.2)   | 21 (61.8)   | n.s. | 10 (52.3)   | 18 (47.3)   | n.s. |
| Current smoker N (% in column) | 5 (9.8)   | 4 (5.6)    | n.s. | 4 (12.5)    | 2 (5.9)     | n.s. | 1 (5.3)     | 2 (5.3)     | n.s. |
| Time since smoking cessation in ex-smokers, mean ± STD | 30.8 ± 14.9 | 33.9 ± 13.8 | n.s. | 29.6 ± 14.5 | 30.8 ± 14.5 | n.s. | 32.7 ± 16.1 | 37.7 ± 12.2 | n.s. |

DBP = diastolic blood pressure, PP = pulse pressure
Table S7. Common medications\textsuperscript{a,b} (sub-cohort with T-cell phenotyping data)

|                                   | All (N = 51) | CMV+ (N = 72) | P  | Male (N = 32) | CMV+ (N = 34) | P  | Female (N = 19) | CMV+ (N = 38) | P  |
|-----------------------------------|--------------|----------------|----|--------------|----------------|----|----------------|----------------|----|
| Cholesterol lowering drugs (all)  |              |                |    |              |                |    |                |                |    |
| CMV-                              | 15 (29.4)    | 14 (19.4)      | n.s.| 12 (37.5)    | 8 (23.5)       | n.s.| 3 (15.8)       | 6 (15.8)       | n.s.|
| CMV+                              | 14 (27.5)    | 14 (19.4)      | n.s.| 11 (34.4)    | 8 (23.5)       | n.s.| 3 (15.8)       | 6 (15.8)       | n.s.|
| Oral anti-hyperglycemic           | 3 (5.9)      | 0 (0.0)        | n.s.| 1 (3.1)      | 0 (0.0)        | n.s.| 2 (10.5)       | 0 (0.0)        | n.s.|
| Blood pressure lowering drugs (any)| 16 (31.4)    | 21 (29.2)      | n.s.| 10 (31.3)    | 9 (26.5)       | n.s.| 6 (31.6)       | 12 (31.6)      | n.s.|
| BP medications (No) mean± STD     | 0.41 ± 0.70  | 0.49 ± 0.91    | n.s.| 0.44 ± 0.75  | 0.50 ± 0.99    | n.s.| 0.37 ± 0.59    | 0.47 ± 0.86    | n.s.|
| Diuretic                          | 2 (3.9)      | 7 (9.7)        | n.s.| 1 (3.1)      | 3 (8.8)        | n.s.| 1 (5.3)        | 4 (10.5)       | n.s.|
| Beta-blocker                      | 6 (11.8)     | 5 (6.9)        | n.s.| 4 (12.5)     | 2 (5.9)        | n.s.| 2 (10.5)       | 3 (7.9)        | n.s.|
| Ca-antagonist                     | 6 (11.8)     | 5 (6.9)        | n.s.| 4 (12.5)     | 3 (8.8)        | n.s.| 2 (10.5)       | 2 (5.3)        | n.s.|
| ACE inhibitor/AT-II receptor antagonist | 10 (19.6)   | 15 (20.8)      | n.s.| 7 (22.2)     | 7 (21.9)       | n.s.| 3 (15.8)       | 8 (21.1)       | n.s.|
| Centrally acting anti-hypertensive| 0 (0.0)      | 1 (1.4)        | n.s.| 0 (0.0)      | 1 (2.9)        | n.s.| 0 (0.0)        | 0 (0.0)        | n.s.|
| Nitroglycerine                    | 0 (0.0)      | 0 (0.0)        | n.s.| 0 (0.0)      | 0 (0.0)        | n.s.| 0 (0.0)        | 0 (0.0)        | n.s.|
| Platelet aggregation inhibitor    | 4 (7.8)      | 9 (12.5)       | n.s.| 3 (9.4)      | 7 (20.6)       | n.s.| 1 (5.3)        | 2 (5.3)        | n.s.|

\textsuperscript{a}Medications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers.

\textsuperscript{b}unless indicated otherwise, values are reported as N (% of group in column)
Table S8. Association between cytomegalovirus seropositivity and CD8 T\textsubscript{mem} population size among the entire sub-cohort with phenotyping data and among men and women separately.

| Sample                                         | Beta coefficient (95% Confidence Interval)\textsuperscript{a} |
|------------------------------------------------|-------------------------------------------------------------|
|                                                 | Model 1\textsuperscript{b}  | Model 2\textsuperscript{c}  | Model 3\textsuperscript{d}  |
| CMV serostatus/all (N = 123)                    | 0.058 (0.029, 0.086)*** | 0.063 (0.034, 0.092)*** | 0.064 (0.034, 0.093)*** |
| Models split by gender:                         |                                                             |
| CMV serostatus/men (N = 66)                     | 0.059 (0.025, 0.092)**  | 0.059 (0.025, 0.093)**  | 0.060 (0.025, 0.094)**  |
| CMV serostatus/women (N = 57)                   | 0.070 (0.020, 0.119)**  | 0.072 (0.022, 0.123)**  | 0.073 (0.021, 0.125)**  |

\textsuperscript{a}log\textsubscript{10} units

\textsuperscript{b}Model 1 unadjusted.

\textsuperscript{c}Model 2 adjusted for age, socioeconomic status, and sex (total sample only).

\textsuperscript{d}Model 3 additionally adjusted for smoking pack-years and waist-to-hip ratio.

*P < 0.05, **P < 0.01, ***P < 0.001
Supplementary Materials:

Materials and methods

Participants and samples

GPs were instructed to search their electronic patient records with respect to the study’s inclusion and exclusion criteria, compile a list of all potentially eligible participants, assign a number to each individual, and communicate the total number eligible to the PCRN. Over several recruitment waves the PCRN provided each practice with a list of random numbers. Larger practices were instructed to reach out to 100 individuals per wave and engaged in more waves than smaller practices, which were instructed to reach out to 50 individuals per wave. For each wave of invitations, new random numbers were sent to each practice (previously used numbers were excluded). Recruitment occurred in multiple waves over a total of 2.5 years. Practices mailed written invitations to all selected individuals. If interested, invited participants contacted the research nurse team at the Clinical Investigation and Research Unit (CIRU) of Brighton and Sussex University Hospital NHS Trust (BSUHT) to schedule an initial screening appointment, which took place in their GP’s practice. At this appointment, inclusion/exclusion criteria were double-checked, written informed consent was obtained from eligible participants, a blood sample was obtained by venepuncture for testing CMV-serostatus, and participants were invited to attend the main study appointment at CIRU.

Participants from a previous study (N = 131) using the same random recruitment approach 3 years earlier, were invited as well (direct mail-out by CIRU). Respondents (N = 30) were invited directly for the main appointment after confirming eligibility via telephone. Their CMV status had previously been recorded but was not a criterion for selection.

At the main study appointment, eligibility of all participants was reviewed, a detailed medical history was obtained, vascular measurements were performed, and additional blood samples were taken for measuring blood counts, lipid values, and general blood biochemistry. Individuals were recruited in the order in which responses were received. Vascular laboratory staff were blinded to the CMV status of participants at all times. Recruitment was continued until N = 209 individuals had attended the main appointment. After reviewing eligibility according to the selection criteria N = 193 participants were eligible for assessment in the vascular lab (Figure S5). Of these, 104 were CMV+ and 89 were CMV-.
Briefly, with the patient in supine position the carotid and femoral arteries are located and the positions where carotid and femoral pressures are to be measured are marked. The distance between these points is measured and recorded in the analysis software. The sensors are positioned on the respective measurement points for data acquisition. During measurement, the time-delay between recording the pulse wave at the carotid and femoral arteries is recorded along with the changes in central and peripheral brachial blood pressure. The analysis software subsequently displays pulse wave velocity and the central (carotid) pressure waveform analysis. Measurement of cfPWV was attempted in 193 and completed in 181 individuals. In 12 individuals the procedure was aborted due to compliance issues. A total of N = 137 (76%) of cfPWV measurements passed quality control (QC) by two physicians blinded to the CMV infection status of participants. QC was based on the shape of the recordings and the consistency (wave form) of the ten consecutive waves. Extreme outliers in terms of cfPWV (> LQ- (3*IQR); < (UQ+3*IQR) were removed during analysis leaving N = 136 accepted measurements for cfPWV.

Whole blood antibody staining for T-cell phenotyping

Fresh, sodium-heparin-anticoagulated whole blood (100 μL) was incubated with monoclonal, fluorescence-labeled staining antibodies as follows. Anti-CD45-AlexaFluor (AF)700, anti-CD3-Pacific Blue (PB), anti-CD4-Brilliant Violet (BV)510, anti-CD8α-allophycocyanin (APC)-H7, anti-CCR7 BV605, anti-CD45RA-Fluorescein-isothiocyanate (FITC) (all BioLegend, Cambridge, UK). Cells were incubated for 20 min at RT in the dark followed by addition of BD lysis buffer (BD) and incubation for 10 min according to the manufacturer’s instructions. Samples were then centrifuged (5 min at 350 g), resuspended in PBS and spun again (5 min at 350g). Finally, cells were fixed (1% paraformaldehyde in water) and washed. Pellets were resuspended in 300 μL of staining buffer (BD) prior to acquisition within 1-4 h.

CMV-peptides

Twenty-five μg per peptide per pool (PepMix™, JPT Peptide Technologies, Berlin, Germany) were dissolved in 100 μL of DMSO (Sigma-Aldrich, Gillingham, UK) (0.25 μg/μL). For T-cell stimulation assays 2 μL of the 0.25 μg/μL CMV-peptide solutions were used for a final concentration of 1 μg/mL per peptide. All assays included a positive control that consisted of 1 μg/ml (final concentration) of Staphylococcal enterotoxin B from Staphylococcus aureus (SEB,
Sigma) dissolved in DMSO, and a negative control consisting of 2 μL of DMSO alone (i.e., the peptide solvent). A list of all CMV proteins used in the study is provided in Table 5.

CMV-reactivity of T-cells
CMV-specific T-cells from CMV+ individuals were activated by incubating PBMC for 16 h overnight (37 °C, humidified 5% CO2 atmosphere) with peptide pools, positive and negative controls. Per tube 1x10^6 PBMCs were incubated with 2 μL of the corresponding CMV peptide pool, 1 μL of SEB solution (positive control, final concentration 1 μg/mL) or 2 μL of DMSO (negative control) in complete RPMI media (final incubation volume 250 μL). After 2 h in a standard incubator (37°C, humidified 5% CO2 atmosphere) each tube received 250 μL of complete RPMI containing 10 μg/mL of Brefeldin A (BFA), resulting in a final volume of 500 μL for the remaining incubation time (14 h). Thereafter each tube was incubated for 10 min at 37 °C (water bath) with 100 μL of 20 mM EDTA (Sigma). Subsequently, samples were washed with 3 mL of wash buffer (PBS with 0.5% w/v BSA and 0.1% w/v sodium azide, Sigma) and centrifuged at 400 g for 8 min at RT (‘wash step’). Samples were then surface-stained (30 min at 4 °C in the dark) with fluorochrome conjugated monoclonal antibodies including anti-CD3 Pacific Blue, anti-CD4 BV510, anti-CD8a PE-Cy7, anti-CCR7 BV605, and anti-CD45RA PerCP/Cy5.5 (all Biolegend), followed by a wash step. Following the surface stain 1 ml of 1x BD ‘FACS Lysing Solution’ (BD) was added to each tube and tubes incubated for 10 min in the dark. Another wash step followed and subsequently, BD ‘Permeabilization solution 2’ was added to each tube and samples were incubated for 10 min in the dark. After a further wash step, cells were stained intracellularly with anti-IL-2 APC, anti-TNFα AF 700 and anti-IFN-γ FITC (all Biolegend) for 30 min at 4 °C in the dark followed by a wash step. Then, 1 mL of 0.5% paraformaldehyde (in water) was added to each tube and incubated in the dark for 5 min. After a final wash step cells were stored at 4 °C in the dark until acquisition.

Data acquisition and analysis
Samples were acquired on an LSR II flow-cytometer (BD). FlowJo v9.x software (Tree Star Inc., Ashland, OR) was used for data analysis. The gating strategies for phenotype staining of whole blood samples and intracellular cytokine staining for PBMC samples are described in Figures S3 and S6, respectively.

Quality control for flow-cytometry
Comparable day-to-day performance of the LSR II flow-cytometer was ascertained by running
CS&T calibration beads (BD) on a daily basis. In addition, 8-peak Rainbow beads were used prior to every run in order to adjust PMTs in such a way that with respect to each detector, every peak was always in the same channel.

**Statistical analysis**

Linear regression models were adjusted for covariates as follows.

(1) Linear regression models testing an association of CMV infection status (CMV+ or CMV-) with cfPWV. First, models were unadjusted. They were then adjusted for sex (total sample only), age, and SES. Next, they were adjusted smoking pack-years and WHR. Finally, models were adjusted for SBP and TC/HDL-C.

(2) Linear regression models testing an association of CMV infection status with \( T_{\text{mem}} \). Initial models were unadjusted. Subsequent models were adjusted for age, SES, and sex (unless stratified by sex). They were then adjusted for smoking pack-years and WHR. Models were not adjusted for SBP and TC/HDL-C as no consistent effect of these parameters on \( T_{\text{mem}} \) is known.

(3) Linear regression models testing an association of \( T_{\text{mem}} \) with cfPWV. Initial models were unadjusted. Subsequent models were adjusted for CMV (unless stratified by CMV), and then age (unless stratified by age) and SES. Finally, models were adjusted for WHR and smoking pack-years. Finally, models were adjusted for SBP and TC/HDL-C. To avoid collinearity, these models were not adjusted for sex, because the effect of sex was already accounted for by the proportions of \( T_{\text{mem}} \) (which were higher in men than in women).

Data trends in scatter plots were visualised using the SPSS ‘fit line’ command (linear model). Bivariate correlations were tested using the ‘correlate’ command in SPSS, the Pearson Correlation Coefficient (R) is reported.
Supplementary Figures

Figure S1. Flowchart describing the recruitment of individuals for measuring PWV and other relevant parameters.
**Figure S2.** cfPWV is higher in CMV+ compared with CMV- older men. Diagrams show the distribution of cfPWV in men and women stratified by CMV infection status. Box plots show median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ+1.5*IQR), outliers (o) and extreme values (×). Significant differences are indicated by P-values.
**Figure S3.** Gating strategy for whole blood surface phenotyping. Lymphocytes were gated in an SSC/FSC plot. Singlets were gated in an FSC-A/FSC-H plot, doublets were excluded. From the singlet gate a CD3 T-cell gate was created in a CD3/CD8 fluorescence dot-plot (top right). A CD4 versus CD8 fluorescence dot plot allowed to visualize T-cell subsets based on CD4 and CD8 expression (middle). For the analysis of CCR7 and CD45RA expression CD4 T-cells (bottom left) and CD8 T-cells (bottom right) were gated separately. The canonical naïve (CCR7+CD45RA+, TNA), central memory (CCR7+CD45RA-, TCM), effector memory (CCR7-CD45RA-, TEM), and revertant memory T-cell subsets (CCR7-CD45RA+, TEMRA) were identified as shown. The same gating sequence and strategy was applied to all samples. The expression of CD28 was used to aid the discrimination between the subsets in that the CCR7+/CD45RA+ subset is CD28bright (not shown).
Figure S4. Differential distribution of canonical CD4 and CD8 memory T-cell subsets in men and women stratified by CMV status. A. Box plots show the distribution of CD4 $T_{\text{NA}}$, $T_{\text{CM}}$, $T_{\text{EM}}$, and $T_{\text{EMRA}}$ subsets in men and women among the entire cohort (top), CMV-individuals (middle) and CMV+ individuals (bottom). B. Box plots show the distribution of the corresponding CD8 T cell subsets in each group. Box plots show median and interquartile range, outlier limits (whiskers, LQ-1.5*IQR, UQ + 1.5*IQR), outliers (o) and extreme values (*). Significant differences are indicated by P-values.
**Figure S5**: Bar charts showing the distribution of CD4 (top) and CD8 (bottom) T-cell responsiveness to 16 different CMV proteins arranged in 14 stimulation pools. Each column represents the number of positive responses among CMV+ people to one stimulation pool. Positive responses were identified by intracellular cytokine staining following stimulation of fresh PBMC with protein-spanning peptide pools.
Figure S6. Gating strategy for ICS on antigen-stimulated, fresh PBMC. (1) Lymphocytes were gated in an SSC/FSC plot. (2) Singlets were gated in an FSC-A/FSC-H plot, and doublets were excluded. (3) From the singlet gate, two CD3 T-cell gates were created, one in a CD3/CD4 fluorescence dot-plot (top right) and one in a CD3/CD8 fluorescence dot-plot. Each gate allowed for inclusion of sometimes strongly TCR downregulated T-cells. (4) The two CD3 gates were then combined in a Boolean gate (OR) for gating CD4 and CD8 T-cells in a CD4 versus CD8 fluorescence dot plot, which allowed to visualize T-cell subsets based on CD4 and CD8 expression. (5) For the analysis of activated T-cells, CD4 and CD8 T-cells were plotted versus the activation markers (IL-2, TNF, and IFN-γ). These gates were overlaid with the canonical memory T-cell subsets defined by CCR7 and CD45RA expression. The same gating sequence and strategy was applied to all samples.
**Supplementary Tables**

**Table S1.** Association between cytomegalovirus serostatus and cfPWV among men and women separately, fully adjusted model

|                | Beta coefficient (95% Confidence Interval)\(^a\) | P value |
|----------------|---------------------------------------------|--------|
| **Men\(^b\)**  |                                            |        |
| CMV serostatus | 0.059 (0.024, 0.093)                         | 0.001  |
| Age            | 0.005 (0.003, 0.008)                         | 0.000  |
| SES            | -0.087 (-0.163, -0.012)                      | 0.024  |
| WHR            | 0.142 (0.017, 0.267)                         | 0.027  |
| Smoking pack-years | 0.000 (-0.006, -0.006)                  | 0.961  |
| TC/HDL-C       | -0.006 (-0.026, 0.014)                      | 0.562  |
| SBP lying      | 0.732 (0.422, 1.041)                         | 0.001  |
| **Women\(^c\)**|                                            |        |
| CMV serostatus | -0.010 (-0.055, 0.035)                      | 0.661  |
| Age            | 0.007 (0.003, 0.011)                         | 0.001  |
| SES            | 0.064 (-0.037, 0.165)                        | 0.212  |
| WHR            | -0.219 (-0.556, 0.118)                      | 0.198  |
| Smoking pack-years | 0.007 (0.000, 0.015)                  | 0.060  |
| TC/HDL-C       | -0.004 (-0.024, 0.032)                      | 0.776  |
| SBP lying      | 1.000 (0.641, 1.359)                         | 0.000  |

SES: socioeconomic standing, WHR: waist over hip ratio, TC/HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure

\(^a\)log10 units

\(^b\)R-squared of fully adjusted model: 0.550

\(^c\)R-squared of fully adjusted model: 0.554
Table S2. Additional information on smoking and blood pressure (entire cohort)

|                      | All | Male | Female |
|----------------------|-----|------|--------|
|                      | CMV- (N = 60) | CMV+ (N = 76) | P       | CMV- (N = 36) | CMV+ (N = 36) | P       | CMV- (N = 24) | CMV+ (N = 40) | P       |
| DBP lying (mmHg)     |     |      |        |        |        |        |        |        |        |        |
| median (IQR)         | 76.8 (11.1) | 74.5 (14.5) | n.s.   | 79.8 (9.1) | 76.0 (19.3) | n.s.   | 73.8 (9.6) | 73.8 (14.1) | n.s.   |
| PP lying (mmHg)      |     |      |        |        |        |        |        |        |        |        |
| median (IQR)         | 58.0 (18.9) | 57.2 (18.1) | n.s.   | 57.5 (16.0) | 58.0 (15.4) | n.s.   | 61.8 (19.5) | 55.0 (23.1) | n.s.   |
| Ever smoker N (% in column) | 32 (53.3) | 43 (57.6) | n.s.   | 19 (52.8) | 23 (63.9) | n.s.   | 13 (54.2) | 20 (50.0) | n.s.   |
| Current smoker N (% in column) | 6 (10.0) | 5 (6.5) | n.s.   | 5 (13.8) | 3 (8.3) | n.s.   | 1 (4.1) | 2 (5.0) | n.s.   |
| Time since smoking cessation in ex-smokers, mean ± STD | 31.7 ± 14.2 | 34.1 ± 13.2 | n.s.   | 29.6 ± 14.5 | 31.0 ± 14.2 | n.s.   | 34.0 ± 14.0 | 37.5 ± 11.5 | n.s.   |

DBP = diastolic blood pressure, PP = pulse pressure
Table S3. Common medications\textsuperscript{a,b} (entire cohort)

|                                | All (N = 76) | Male (N = 36) | Female (N = 40) |
|--------------------------------|--------------|---------------|-----------------|
|                                | CMV\textsuperscript{-} | CMV\textsuperscript{+} | P   | CMV\textsuperscript{-} | CMV\textsuperscript{+} | P   | CMV\textsuperscript{-} | CMV\textsuperscript{+} | P   |
| Cholesterol lowering drugs (all) | 17 (28.3)    | 14 (18.4)     | n.s. | 14 (38.9)    | 8 (22.2)     | n.s. | 3 (12.5)     | 6 (15.0)     | n.s. |
| Statin                         | 16 (26.7)    | 14 (18.4)     | n.s. | 13 (36.1)    | 8 (22.2)     | n.s. | 3 (12.5)     | 6 (15.0)     | n.s. |
| Oral anti-hyperglycemic        | 3 (5.0)      | 0 (0.0)       | n.s. | 1 (2.8)      | 0 (0.0)      | n.s. | 2 (8.3)      | 0 (0.0)      | n.s. |
| Blood pressure lowering drugs (any) | 18 (30)    | 22 (28.9)     | n.s. | 11 (30.6)    | 9 (25.0)     | n.s. | 7 (29.2)     | 13 (32.5)    | n.s. |
| Blood pressure lowering drugs (number) | 0.43 ± 0.77 | 0.49 ± 0.92   | n.s. | 0.44± 0.77   | 0.47± 0.97   | n.s. | 0.42± 0.77   | 0.50± 0.87   | n.s. |
| Diuretic                       | 3 (5.0)      | 8 (10.5)      | n.s. | 1 (2.8)      | 3 (8.3)      | n.s. | 2 (8.3)      | 5 (12.5)     | n.s. |
| Beta-blocker                   | 8 (13.3)     | 5 (6.6)       | n.s. | 5 (13.9)     | 2 (5.6)      | n.s. | 3 (12.5)     | 3 (7.5)      | n.s. |
| Ca-antagonist                  | 6 (10.0)     | 5 (6.6)       | n.s. | 4 (11.1)     | 3 (8.3)      | n.s. | 2 (8.3)      | 2 (5.0)      | n.s. |
| ACE inhibitor/AT-II receptor antagonist | 12 (20)    | 16 (21.1)     | n.s. | 8 (22.2)     | 7 (19.4)     | n.s. | 4 (16.7)     | 9 (22.5)     | n.s. |
| Centrally acting anti-hypertensive | 0 (0.0)   | 1 (1.3)       | n.s. | 0 (0.0)      | 1 (2.8)      | n.s. | 0 (0.0)      | 0 (0.0)      | n.s. |
| Nitroglycerine                 | 0 (0.0)      | 0 (0.0)       | n.s. | 0 (0.0)      | 0 (0.0)      | n.s. | 0 (0.0)      | 0 (0.0)      | n.s. |
| Platelet aggregation inhibitor | 6 (10.0)     | 9 (11.8)      | n.s. | 5 (13.9)     | 7 (19.4)     | n.s. | 1 (4.2)      | 2 (5.0)      | n.s. |

\textsuperscript{a}Medications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers.

\textsuperscript{b}Unless indicated otherwise, values are reported as N (% of group in column)
Table S4. Association between cytomegalovirus serostatus and cfPWV among the entire cohort and among men and women separately

| CMV serostatus/all (N = 136) | Beta coefficient (95% Confidence Interval)\(a\) | Model 4A<sup>b</sup> | Model 4B<sup>c</sup> |
|------------------------------|-----------------------------------------------|-----------------------|-----------------------|
| CMV serostatus/men (N = 72) | 0.021 (-0.008, 0.049) | 0.022 (-0.006, 0.050) |
| CMV serostatus/women (N = 64)| -0.011 (-0.056, 0.035) | -0.011 (-0.056, 0.033) |

<sup>a</sup>log10 units  
<sup>b</sup>Model 4A corresponds to Model 4 in Table 2, additionally adjusted for the number of anti-hypertensive medications taken.  
<sup>c</sup>Model 4B corresponds to Model 4 in Table 2, additionally adjusted for presence/absence of antihypertensive medication (yes/no)  
*<sup>P</sup> < 0.05; **<sup>P</sup> < 0.01
### Table S5. Characteristics used in linear regression models (sub-cohort with T-cell phenotyping data)\(^a\)

|                       | All (N = 51) | Male (N = 32) | P    | All (N = 72) | Male (N = 34) | P    | All (N = 38) | Male (N = 34) | P    |
|-----------------------|--------------|---------------|------|--------------|---------------|------|--------------|---------------|------|
| PWV (m/s) median (IQR)| 9.5 (3.4)    | 9.4 (3.0)     | n.s. | 8.9 (2.9)    | 10.1 (2.5)    | 0.029 | 9.8 (4.3)    | 8.9 (3.3)     | n.s. |
| Age years mean ± STD  | 69.1 ± 7.4   | 70.4 ± 7.2    | n.s. | 69.7 ± 7.8   | 71.0 ± 8.7    | n.s. | 68.1 ± 6.8   | 69.8 ± 5.6    | n.s. |
| SES median (IQR)      | 4.3 (3.9)    | 6.0 (4.8)     | n.s. | 4.2 (3.9)    | 6.0 (5.2)     | n.s. | 5.0 (3.0)    | 4.7 (3.1)     | n.s. |
| Smoking (pack-years)  | 0.5 (13.0)   | 0.1 (6.8)     | n.s. | 1.3 (12.5)   | 1.1 (23.1)    | n.s. | 0.5 (15.0)   | 0.0 (3.2)     | n.s. |
| WHR mean ± STD        | 1.0 ± 0.2    | 0.9 ± 0.1     | n.s. | 1.0 ± 0.20   | 1.0 ± 0.1     | n.s. | 0.9 ± 0.0    | 0.9 ± 0.1     | n.s. |
| TC/HDL-C mean ± STD   | 3.4 ± 0.9    | 3.2 ± 0.8     | n.s. | 3.5 ± 0.9    | 3.3 ± 0.8     | n.s. | 3.1 ± 1.0    | 3.0 ± 0.8     | n.s. |
| SBP lying (mmHg) median (IQR) | 142 (18) | 135 (26) | n.s. | 141 (16) | 137 (24) | n.s. | 142 (25) | 131 (28) | n.s. |

SES: socioeconomic standing, WHR: waist over hip ratio, TC/HDL-C: total cholesterol over HDL cholesterol, SBP: systolic blood pressure

\(^a\)Parameters for which median (IQR) is provided were log-transformed for use in linear regression models
Table S6. Additional information on smoking and blood pressure (sub-cohort with T-cell phenotyping data)

|                      | All          | Male        | Female       |     |
|----------------------|--------------|-------------|--------------|-----|
|                      | CMV- (N=51)  | CMV+ (N=72) | P            | CMV- (N=19) | CMV+ (N=38) | P |
| DBP lying (mmHg)     |              |             | n.s.         |              |              |    |
| median (IQR)         | 77.5 (10.0)  | 74.8 (14.8) | n.s.         | 74.5 (10.0)  | 73.8 (14.1)  | n.s. |
| PP lying (mmHg)      |              |             | n.s.         |              |              |    |
| median (IQR)         | 58.5 (18.5)  | 57.3 (18.1) | n.s.         | 68.5 (21.5)  | 54.0 (23.1)  | n.s. |
| Ever smoker N (%) in column | 28 (55.0)  | 39 (54.1)   | n.s.         | 10 (52.3)    | 18 (47.3)    | n.s. |
| Current smoker N (%) in column | 5 (9.8)     | 4 (5.6)     | n.s.         | 1 (5.3)      | 2 (5.3)      | n.s. |
| Time since smoking cessation in ex-smokers, mean ± STD | 30.8 ± 14.9 | 33.9 ± 13.8 | n.s.         | 32.7 ± 16.1  | 37.7 ± 12.2  | n.s. |

DBP = diastolic blood pressure, PP = pulse pressure
|                                | All (N = 51) | CMV+ (N = 72) | P   | Male (N = 32) | CMV+ (N = 34) | P   | Female (N = 19) | CMV+ (N = 38) | P   |
|--------------------------------|--------------|---------------|-----|---------------|---------------|-----|----------------|---------------|-----|
| **Cholesterol lowering drugs (all)** |              |               |     |               |               |     |                |               |     |
| CMV-                            | 15 (29.4)    | 14 (19.4)     | n.s.| 12 (37.5)     | 8 (23.5)      | n.s.| 3 (15.8)       | 6 (15.8)      | n.s.|
| CMV+                            |              |               |     |               |               |     |                |               |     |
| **Statin**                      | 14 (27.5)    | 14 (19.4)     | n.s.| 11 (34.4)     | 8 (23.5)      | n.s.| 3 (15.8)       | 6 (15.8)      | n.s.|
| **Oral anti-hyperglycemic**      | 3 (5.9)      | 0 (0.0)       | n.s.| 1 (3.1)       | 0 (0.0)       | n.s.| 2 (10.5)       | 0 (0.0)       | n.s.|
| **Blood pressure lowering drugs (any)** | 16 (31.4)  | 21 (29.2)     | n.s.| 10 (31.3)     | 9 (26.5)      | n.s.| 6 (31.6)       | 12 (31.6)     | n.s.|
| **BP medications (No)**         | 0.41 ± 0.70  | 0.49 ± 0.91   | n.s.| 0.44 ± 0.75   | 0.50 ± 0.99   | n.s.| 0.37 ± 0.59    | 0.47 ± 0.86   | n.s.|
| mean± STD                       |              |               |     |               |               |     |                |               |     |
| **Diuretic**                    | 2 (3.9)      | 7 (9.7)       | n.s.| 1 (3.1)       | 3 (8.8)       | n.s.| 1 (5.3)        | 4 (10.5)      | n.s.|
| **Beta-blocker**                | 6 (11.8)     | 5 (6.9)       | n.s.| 4 (12.5)      | 2 (5.9)       | n.s.| 2 (10.5)       | 3 (7.9)       | n.s.|
| **Ca-antagonist**               | 6 (11.8)     | 5 (6.9)       | n.s.| 4 (12.5)      | 3 (8.8)       | n.s.| 2 (10.5)       | 2 (5.3)       | n.s.|
| **ACE inhibitor/AT-II receptor antagonist** | 10 (19.6) | 15 (20.8)     | n.s.| 7 (22.2)      | 7 (21.9)      | n.s.| 3 (15.8)       | 8 (21.1)      | n.s.|
| **Centrally acting anti-hypertensive** | 0 (0.0)     | 1 (1.4)       | n.s.| 0 (0.0)       | 1 (2.9)       | n.s.| 0 (0.0)        | 0 (0.0)       | n.s.|
| **Nitroglycerine**              | 0 (0.0)      | 0 (0.0)       | n.s.| 0 (0.0)       | 0 (0.0)       | n.s.| 0 (0.0)        | 0 (0.0)       | n.s.|
| **Platelet aggregation inhibitor** | 4 (7.8)     | 9 (12.5)      | n.s.| 3 (9.4)       | 7 (20.6)      | n.s.| 1 (5.3)        | 2 (5.3)       | n.s.|

*a* Medications beyond the listed categories included commonly prescribed drugs for the management of chronic pain, hypothyroidism, osteoporosis, COPD, asthma, allergies, constipation, skin conditions, and gastritis/ulcers.

*b* unless indicated otherwise, values are reported as N (% of group in column)
Table S8. Association between cytomegalovirus seropositivity and CD8 T<sub>mem</sub> population size among the entire sub-cohort with phenotyping data and among men and women separately

| Sample                                      | Beta coefficient (95% Confidence Interval)<sup>a</sup>         |
|---------------------------------------------|--------------------------------------------------------------|
|                                             | Model 1<sup>b</sup>                                         |
| CMV serostatus/all (N = 123)               | 0.058 (0.029, 0.086)***                                     |
| CMV serostatus/men (N = 66)                | 0.059 (0.025, 0.092)**                                       |
| CMV serostatus/women (N = 57)              | 0.070 (0.020, 0.119)**                                       |
| Models split by gender:                    |                                                               |
| CMV serostatus/men (N = 66)                | 0.059 (0.025, 0.093)**                                       |
| CMV serostatus/women (N = 57)              | 0.072 (0.022, 0.123)**                                       |
| CMV serostatus/women (N = 57)              | 0.073 (0.021, 0.125)**                                       |

<sup>a</sup>log10 units
<sup>b</sup>Model 1 unadjusted.
<sup>c</sup>Model 2 adjusted for age, socioeconomic status, and sex (total sample only).
<sup>d</sup>Model 3 additionally adjusted for smoking pack-years and waist-to-hip ratio.

*P < 0.05, **P < 0.01, ***P < 0.001